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ABSTRACT
Herpes simplex virus (HSV) infection of the cornea leads to a blinding immunoinflammatory condition of the eye also called stromal keratitis (SK). SK
immunopathology is characterized by the infiltration of CD4+ T cells of Th1 phenotype
as well as the development of new blood vessels into the normally avascular cornea.
Studies in mouse models of SK have firmly established the role of CD4+ T cells, and
particularly of Th1 phenotype, as the principal mediators of SK immunopathology.
However, with the recent discovery of IL-17A and Th17 cells, the role of this cytokine as
well as Th17 cells remains to be further defined. Recently it was shown that the normal
cornea expresses VEGF-A, however its biological activity is impeded by its binding to a
soluble form of VEGF-A receptor-1 (sVEGFR-1). Past studies have implicated the role
of vascular endothelial growth factor-A (VEGF-A) in HSV induced corneal angiogenesis,
however the source of VEGF-A as well as molecular mechanisms, particularly in the
context of VEGF-A/sVEGFR-1 balance during HSV infection, are poorly understood.
The first part of this dissertation (I) reviews past literature on HSV induced
corneal SK immunopathology. It focuses on the understanding of HSV-1 induced events
that particularly results in corneal angiogenesis as well as tissue damage mediated by
different type of cells as well as their secreted products. The next three parts (II-IV) focus
on the mechanisms of HSV induced corneal angiogenesis as well as the relative role of
Th1 and Th17 cells in SK immunopathology. Results in part II focuses on the relative
role of IFN-γ/IL-17 as well as Th1/Th17 cells in HSV induced corneal
immunopathology. The third section evaluate the significance of VEGF-A/sVEGFR-1
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balance in HSV induced corneal neovascularization. Results in part IV focus on the role
of IL-17A in altering the balance between VEGF-A and sVEGFR-1 post ocular HSV
infection and subsequent corneal angiogenesis.
Collectively these studies identified novel mechanisms by which HSV infection
of the cornea leads to the development of angiogenesis as well as corneal tissue damage
and subsequent SK immunopathology, the most common cause of infectious blindness in
the Western World.
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BACKGROUND AND OVERVIEW
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HERPES SIMPLEX VIRUS-1 (HSV) and Ocular Immunopathology
Herpes viruses are highly successful pathogens owing to some of the mechanisms
to resist removal from host once they have caused infection (1-4). The transmission of
HSV infection occurs through intimate contact with mucosal surfaces or abraded skin and
oropharyngeal mucosa is the most common site for HSV-1 infection (5). HSV-1 initially
replicates at the site of primary infection in the epithelial layer, followed by retrograde
migration of intact virions to the trigeminal ganglion (TG) where infection is maintained
in a latent state (5-7). During latency, the production of new replication competent virus
is usually absent, however, immune suppression of the host can result in reactivation of
the virus from latently infected TG (2, 3). After reactivation, the virus generally migrates
to the initial site of infection and can lead to development of a variety of immunoinflammatory reactions depending upon the site of recurrent infection (6, 7). When
corneal epithelial cells are the site of infection, a chronic immuno-inflammatory
condition may result, which is termed as herpetic stromal keratitis (SK) that can cause
damage to normal vision (8).
SK is the commonest cause of infectious blindness in the Western World.
According to a recent study it is estimated that in the USA 400,000 persons are affected
with 20,000 new cases of SK occurring annually (4). In humans, SK usually occurs
following the reactivation of the virus from TG (8). The human SK pathogenesis is very
complex, but thought to represent a CD4+ T cell orchestrated inflammatory reaction (8).
Most of our knowledge of various events of SK pathogenesis is based on studies on
experimental SK in animal models, particularly using the immunocompetent mouse as a
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host for primary infection (Fig 1.1) (9-11). In this model, CD4+ T cells primarily
orchestrate the SK lesions, however the exact nature of epitopes for these cells is still
unidentified (9-11). Characteristically, SK lesions are also marked by the development of
pathological angiogenic responses in the cornea that can be extensive and further impair
normal vision (4, 12). Thus the clinical phase of SK pathogenesis involves at least two
significant events, the migration of CD4+ T cells in the corneal stroma and the
development of new blood vessels in the normally avascular cornea (Fig 1.1, 1.2)
Currently, therapeutic intervention of SK usually involves a combination of antiviral and anti-inflammatory drugs (13-15). However, to control the perpetuating
inflammatory

reaction,

long

periods

of

anti-inflammatory

drugs,

particularly

corticosteroids, are administered which can have serious side effects such as risk of
cataract formation and glaucoma (13-15). Additionally, in some patients corticosteroids
may promote HSV replication thereby worsening the SK lesion severity (16). Thus there
is a need for the development of new and alternative therapeutic strategies to control SK.
Understanding various molecular mechanisms responsible for development of complex
SK lesion could shed light on possible targets for better control of SK pathology.

Pathogenesis of SK
In the mouse model, primary ocular infection with HSV is followed by initial
replication of virus in the corneal epithelium for up to 5-6 days (Fig 2) (4). Live viral
particles, as well as transcribed mRNA copies of viral genes were detected from the
corneal swabs during early time points up to day 7 post infection (pi). However, viral
DNA was detected in the cornea up to day 21 pi when SK lesions were fully evident (4).
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Early after HSV infection, a prominent infiltration of innate inflammatory cells,
particularly neutrophils, occured in corneal stromal layer adjacent to infected corneal
epithelial cells (17). Neutrophils primarily migrated from the limbal blood vessels
conceivably in response to various chemokine signals released after initial virus infection
(4, 17). Neutrophil influx was characterized by a biphasic response in which initial
infiltration started around 18 hrs pi, peaked at day 2 pi followed by a decline reaching to
undetectable levels around day 5 pi. A second wave of neutrophil infiltration started from
day 7 pi that persisted throughout the course of the clinical phase of SK (4, 17, 18).
Although, neutrophils initially played a protective role in the virus clearance (19),
subsequently during the clinical phase of SK they contributed to the corneal tissue
damage and angiogenesis (17, 18). Thus depletion of neutrophils during early stages of
HSV infection with specific monoclonal antibody mAb led to higher viral titers as well as
delayed clearance of virus from the cornea (19). However, depletion of neutrophils
during the clinical phase of SK resulted in significantly diminished angiogenesis as well
as reduced SK lesion severity (18). This reduced inflammatory condition post neutrophil
depletion was the result of reduced levels of various molecules secreted by neutrophils,
which contribute to the tissue damage. Neutrophils through their degranulation and
release of various factors such as nitirci oxide (NO), matrix metalloproteinases (MMPs),
VEGF-A, IL-1β, IL-8, IL-12 and TNF-α contributed to the ongoing inflammation and
further tissue destruction which may unmask corneal auto-antigens (4, 20-24). VEGF-A
and MMP-9 play an important role in HSV induced corneal neovascularization
(described later) (18, 23).
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In addition to neutrophils, other innate immune cells such as DCs, NK cells, γδ-T
cells and macrophages also participate in viral clearance and the subsequent
inflammation by secreting various effector molecules such as type I IFNs, cytokines and
chemokines (IL-17, IL-1β, IL-12, MIP-2 TNF-α, IFN-γ, IL-23) (4). Among these various
cytokines, IL-1β and IL-6 were demonstrated to have a critical and central role in
orchestrating the early inflammatory reaction (25-27). Although, after productive HSV
infection of epithelial cells, most host gene expression is turned off (27), expression of
pro-inflammatory cytokines such as IL-6 and IL-1β is increased at least for an initial
period (day 1-2 post infection) and may represent a significant initial source of these
cytokines (4, 27-29). Furthermore, uninfected corneal epithelial cells become the
significant producers of IL-6 and IL-1β (4). However, it is still poorly understood how
the uninfected corneal epithelial cells are programmed to produce these cytokines. One
possible explanation for this is that pathogen associated molecular patterns (PAMPs)
expressed by virus-infected cells or perhaps extracellular virus itself could activate
various pattern recognition receptors. These include Toll-like receptors (TLR)-2, 4, and 9
with subsequent activation of NFκB pathway causing them to synthesize and secrete
cytokines (4, 30, 31). Evidence for this is that CpG motifs derived from viral DNA in the
cornea could stimulate TLR-9 and induce IL-1β and IL-6 that act in a paracrine fashion
on other cells and induce them to secrete various inflammatory mediators that contribute
to the immunopathological lesion as well as induction of adaptive immune response (30,
32, 33). Furthermore, IL-1β acts in a paracrine fashion on un-infected corneal epithelial
cells and stimulates the production of IL-6 (34, 35). IL-6 triggers the synthesis of MIP-2
(CXCL8), which is involved in neutrophil influx at the site of inflammation. In addition
	
  

5	
  

to IL-1β and IL-6, TNF-α also plays an important role in SK pathogenesis, as indicated
by studying SK pathogenesis in mice lacking TNF-α. These results showed that such
mice were unable to control virus replication in the cornea and as a consequence
exhibited an enhanced SK lesion severity (4, 34-37). Thus early events after HSV
infection trigger the production of various cytokines and chemokines, which initiate the
innate immune response and set the stage for further adaptive immune response as well as
immunopathology.

Is SK Immunopathology: Th1 or Th17 mediated?

Early events of the innate immune response drive various critical events that
ultimately result in the adaptive immune response. IL-12 is another critical cytokine that
is produced by neutrophils, macrophages and Langerhans DCs and plays an important
role in SK pathogenesis (4, 38-40). IL-12 stimulates the production of IFN-γ by
macrophages, NK cells, neutrophils as well as CD4+ T cells (40, 41). IFN-γ has been
shown to exert both pro-inflammatory and anti-inflammatory activity (4). It promotes
neutrophil infiltration at the site of inflammation through upregulation of PECAM-1 and
ICAM-1 on corneal epithelial cells (42, 43). Studies in an animal model of SK have
revealed a critical contribution of CD4+ T cells of the Th1 subset as principal
orchestrators of SK lesions (44, 45). However, the identity of target antigens that drive
SK Th1 cells generation during SK immunopathology is poorly understood (4, 44, 45). It
is anticipated that initial corneal infiltrating Th1 cells are HSV specific, however later on
SK lesion would be dominated by bystander cell population (Ref).
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Recent work has revealed the critical pro-inflammatory role of IL-17A in
pathogenesis of many inflammatory and autoimmune diseases (46-48). IL-17 mediates
the local inflammatory response by stimulating epithelial, endothelial and fibroblastic
cells and inducing the release of various inflammatory cytokines (49). IL-17A drives
increased influx as well as survival of neutrophils at the site of inflammation by induction
of neutrophil chemoattractant as well as GM-CSF mediated granulopoeisis (50, 51). IL17A signals through a homodimeric IL-17A receptor A (IL-17RA), which is expressed
ubiquitously, with higher levels in hematopoietic tissues (52, 53). Signaling through IL17RA activates both NFκB and Jnk kinase pathway, resulting in an increased expression
as well as an improved mRNA stability of various pro-inflammatory cytokines (52, 53).
In the beginning, IL-17A was thought to be primarily produce by activated CD4+
memory T cells (49), however, subsequent studies showed that CD8+ memory T cells
can also produce IL-17A upon activation (54). More recently, pioneering studies have
revealed a new subset of CD4+ T cells as IL-17 producers and referred as T helper 17
(Th17). 55, 56). Naïve CD4+ T cells differentiate into Th17 cells under optimum
antigenic stimulation in the presence of TGF-β and IL-6. This drives the subsequent
activation of signal transducer and activator of transcription 3 (STAT3) followed by
expression of retinoic acid related orphan receptor γt (RORγt) (57-60).
Th17 cells play a critical role in defense against fungi and extracellular bacteria
(60). Additional studies implicated the crucial role of Th17 cells in chronic inflammatory
as well as autoimmune pathologies (60). However, slower development of adaptive Th17
responses indicated the possibility of an innate source of IL-17, which contributed to the
early defense mechanism against certain microorganisms (61-63). In addition to Th17
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cells, IL-17A is also produced by γδ T cells, NK cells, NKT cells, alveolar macrophages
as well as neutrophils (63). These studies collectively indicate an important role of IL-17
in innate as well as adaptive immune responses.
Although, Th1 cells constitute a significant proportion of cells during the
development of SK lesions, the actual tissue damage appears to be the consequence of
inflammatory events that derive primarily from neutrophils. The later cell represents the
major cellular component of lesions at all phases of SK pathogenesis (18). The
prominence of neutrophils in SK lesions as well as the role of IL-17A in neutrophil
migration could indicate that the recently identified proinflammatory cytokine IL-17A
may participate in the pathogenesis of lesion development. The role of IFN-γ producing
Th1 cells is well studied in HSV induced corneal immunopathology, but the role of IL-17
and Th17 cells is poorly understood. In human SK, the presence of IL-17 has been
reported (64). Additionally, the Lausch group showed that the severity of early SK
lesions was diminished in mice unable to respond to IL-17 because they lacked the IL-17
receptor (65). However, the cellular source of IL-17 as well as the role this cytokine plays
compared to other inflammatory mediators remains to be further defined. Since, Th17
cells have less stringent requirements for antigenic stimulation (66), it is possible that
Th17 cells may play an important role in SK pathogenesis during later stages when viral
antigen availability is limited. Thus, it could be possible that during the acute phase of
SK pathogenesis HSV specific Th1 cells might dominate while HSV non-specific Th17
cells may maintain the later chronic phase. This was a driving issue that was evaluated in
our studies with the results described in chapter II.
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HSV Induced Corneal Angiogenesis
Another important feature of SK pathogenesis is the development of new blood
vessels or angiogenesis in the normally avascular cornea, which together with increased
corneal opacity due to infiltration of inflammatory cells impairs normal vision and may
lead to blindness (4, 12, 18, 24, 33). Angiogenesis is the formation of new blood vessels
from pre-existing blood vessels through an angiogenic remodeling and sprouting of preexisting angiogenic structures. Development of vasculature (Vasculogenesis) ceases after
complete maturation of the blood vessels and most of the blood vessels remain in
quiescent stages. However, the body needs to respond to various physiological stimuli
and active angiogenesis can be noted in cycling ovary as well as placental development
during pregnancy (67). In addition, various pathological conditions leading to hypoxia
such as ischemia, tissue injury or inflammation necessitates the supply of oxygenated
blood to the damaged tissue (67, 68). Although, blood vessels in adults are maintained in
a quiescent state, various stimuli such as malignancy, tissue injury, ischemia,
inflammation etc can break this quiescence leading to angiogenic sprouting from existing
vessels. This form of angiogenesis is often referred to as pathological angiogenesis and
plays an important role in pathogenesis of various diseases such as cancer, corneal and
retinal disorders (4, 67, 68).
Pathological angiogenesis when compared to physiological angiogenesis, is less
complex and may involve the action of a single growth factor, VEGF-A and its receptors
(68). Additionally, it is not a tightly controlled process and unbalanced growth of vessels
often results in extensive proliferation, irregular branching with the lack of a proper and
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functional hierarchical pattern as observed during normal angiogenesis (68).
Furthermore, due to lack of appropriate remodeling and maturation, these newly formed
vessels are often tortuous, abnormally developed with a large diameter, and leaky. This
leads to severe edema in affected tissue. Moreover, a recent study revealed a differential
gene expression pattern in endothelial cells during physiological and pathological
angiogenesis, indicating the differential regulation of these processes (67-71). Apparently
the neovascularization process looks simpler, but involves various molecular events
similar to those of physiological angiogenesis. The various processes such as angiogenic
sprouting from capillary endothelial cells, their proliferation, migration to the desired
region, organization into tubular structures along with acquisition of pericytes and
smooth muscle cells are essential for the proper development of functional vessels (67,
68, 70, 71). In addition, degradation of the complex extracellular matrix is also essential
for the development of luminal structures in solid tissue. All these events are orchestrated
and coordinated by VEGF-A, different growth factors, matrix-metalloproteinases
(MMPs) with spatial and temporal cues from inflammatory cells. These cells serve as
additional sources of VEGF-A, MMPs, different cytokines and growth factors (67, 68,
70, 71). The role of VEGF-A in pathological angiogenesis as well as structural details of
various types of blood vessels after ectopic VEGF-A expression are well summarized in
the review by Nagy et al (68).
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Corneal Neovascularization: An Essential Step in SK pathogenesis
Corneal transparency is an essential requisite for optimal vision (72, 73) . The
avascularity of cornea is achieved through a fine balance between pro and antiangiogenic factors (72, 73). Events that cause angiogenesis are disruptive to vision such
as occurs after HSV infection of the cornea (4, 12, 24). In mice, HSV infection of the
cornea results in sprouting of new blood vessels from limbal vessels as early as day 1 pi
and reaches the central cornea by day 20 pi (12, 24). The newly formed vascular bed is
often leaky and abnormal releasing inflammatory cells and cytokines into the corneal
stroma giving rise to corneal opacity and haze and subsequent vision impairment (4, 12,
24, 37). Although numerous studies in the past have shed light on several events
responsible for corneal angiogenesis post HSV infection, the exact molecular
mechanisms for this outcome are still poorly understood (4, 12, 24, 33, 37). Interestingly,
HSV replication in corneal epithelium results in angiogenesis in the underlying stroma
(4). Additionally, HSV does not encode any proteins, that is directly angiogenic as does
occurs with some other viruses such as human herpes virus 8 and Orf virus (4, 74-77).
Therefore, the mechanisms by which HSV infection drives corneal angiogenesis could
involve a cascade of indirect events driven by different pro-angiogenic cytokines and
factors (4). Numerous studies from our lab as well as other’s have indicated the several
angiogenic factors can be involved. These include VEGF-A, basic Fibroblast growth
factor (bFGF), bioactive CpG motifs, pro-inflammatory cytokines (IL-6, IL-1β) as well
as E-L-R motif containing chemokines in HSV induced corneal neovascularization (12,
23, 37). Although all these molecules may participate in pathological neovascularization,
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the VEGF family of proteins, especially VEGF-A signaling through the VEGFR-2
receptor, is likely to be the most consequential (12, 78). In support of this, inhibiting
VEGF or interfering with its receptor function, have been shown to be effective
therapeutic strategies in mice models of SK (4, 12, 24, 78).

Source of VEGF-A During HSV Induced Ocular Neovascularization
After ocular HSV infection of mice, VEGF-A mRNA transcripts are detectable by
12 h pi and VEGF-A protein by 24 h pi (4, 12). However, one unresolved issue with
regard to VEGF and pathological angiogenesis in SK, is the source of the VEGF A that
induces the neovascularization as a consequence of the infection. Earlier studies from our
lab demonstrated that the primary source of VEGF-A was corneal uninfected epithelial
cells exposed to stimulating products such as IL-6 and CpG nucleotides released from
infected and dying cells (4, 12). However, more recently, it was observed that VEGF-A
can be produced directly by corneal epithelial cells in response to HSV infection (79).
Additionally, infiltrating inflammatory cells, especially neutrophils, could also contribute
to the source of VEGF-A (4, 18, 22). Interestingly, it was observed that VEGF-A is
continuously produced in biologically functional amounts by normal uninfected corneal
epithelial cells (73). However, this source of VEGF-A fails to induce abnormal
angiogenesis because it is bound to a soluble form of the VEGF receptor 1 (sVEGFR-1)
(73). This inhibitory interaction between VEGF-A and sVEGFR-1 was suggested to
explain corneal avascularity, which is an essential feature of uninterrupted vision (72,
73). Furthermore, an angiogenic response was observed in the normal eyes when the
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bond between VEGF-A and sVEGFR-1 was disrupted using anti-sVEGFR-1 mAb (73).
Also, some species fail to express sVEGFR-1 and in one genetic disease of humans,
synthesis of the sVEGFR-1 molecule is defective (80). In light of the existence of the
VEGF-A trap in normal eyes it could be that pathological angiogenesis, as for example
can occur after HSV infection, could also be influenced by the balance between VEGF-A
and the sVEGFR-1 molecules. We analyzed this possibility as one of the possible
mechanism employed by HSV infection for corneal angiogenesis. Our results indicated
that HSV infection of the cornea leads to an imbalance between VEGF-A and sVEGFR-1
in favor of increased free VEGF-A thus leading to the development of angiogenesis
(Discussed in Part III).

Role of other pro-angiogenic factors in HSV induced corneal neovascularization

a. CpG Motifs
In addition to the direct production of VEGF-A by HSV infected or uninfected
corneal epithelial cells, other factors such as CpG motifs derived from viral DNA can
stimulate paracrine production of VEGF-A by corneal epithelial and stromal cells (4, 33).
However, it is poorly understood how CpG motifs stimulate VEGF-A production. It is
possible that HSV DNA, a rich source of bioactive CpG motifs, can stimulate VEGF-A
production through TLR-9 mediated signaling that leads to induction of MyD88 adaptor
protein and subsequent induction of NFκB pathways (4, 33). Additionally, CpG repeats
induced by HSV infection could stimulate VEGF-A induction through increased
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production of IL-1 and IL-6, which promote paracrine expression of VEGF-A by corneal
epithelial cells (4).

b. Matrix Metalloproteinases (MMPs)
Different MMPs play an important role in the breakdown of solid extracellular
matrix and facilitates migration of endothelial cells, an essential step for the development
of new blood vessel in solid tissue (4, 72, 81). MMPs are zinc-containing proteinases,
secreted as pro-peptides that are activated in the extracellular milieu. They contribute to
extracellular matrix remodeling (81). Several MMPs are expressed and localized to the
different sites in the cornea, and they have been shown to play a role in
neovascularization (72, 81). MMP-2, -7, -9, -14 were considered to be pro-angiogenic in
corneal neovascularization and wound healing (72, 81). Among different MMPs, MMP-9
was shown to play an important role in HSV induced corneal angiogenesis (23). Innate
cells, particularly neutrophils were shown to contribute to the early source of MMP-9,
since depletion of neutrophils with specific mAb after HSV infection resulted in reduced
levels of MMP-9 compared to isotype control antibody treated mice (23). Although,
inhibition of MMP-9 activity using siRNA resulted in diminished angiogenesis severity
in HSV infected mice, the exact molecular mechanism underlying the MMP-9 mediated
neovascularization is poorly understood (4).

c. E-L-R motif containing chemokines
It has been documented that chemokines with E-L-R (tri-peptide sequence
Glutamate-Leucine-Arignine) motifs possess angiogenic activity (4, 82, 83). HSV
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infection of epithelial cells has been shown to up-regulate the expression of one such
chemokine, MIP-2 (36, 84, 85). MIP-2 induced during HSV infection promotes the
neutrophil migration at the site of inflammation thus contributing indirectly to the source
of VEGF-A (36). Neutrophils, further contribute to the angiogenic response as they act as
a source of preformed VEGF-A (22) as well as MMP-9 (23). Thus various chemokines
promoting the migration of neutrophils could contribute indirectly the source of proangiogenic factors and subsequent angiogenesis after corneal HSV infection.

d. Pro-inflammatory cytokines: IL-1β, IL-6 and IL-17
It is known that productive HSV infection of corneal epithelial cells shuts host
protein synthesis (86), but evidence suggests that some pro-inflammatory cytokine genes
such as IL-1β and IL-6 are upregulated by HSV infected cells (27-29). After HSV
infection of mouse corneal epithelial cells, both IL-1β and IL-6 expression is increased at
day 1 pi followed by peak expression at day 10 pi (4, 27-29). Both IL-1β and IL-6 can be
potent inducers of VEGF-A expression (87-90). Furthermore, studies from our lab have
confirmed the role of IL-1β and IL-6 in the induction of VEGF-A by corneal epithelial as
well as stromal fibroblast cells (4, 36, 91). In addition, intrastromal injection of IL-1β and
IL-6 results in corneal angiogenesis in a VEGF-A dependent manner indicating their
critical role in the induction of VEGF-A (4, 36, 91). Accordingly, blocking of IL-1β with
the IL-1 receptor antagonist or neutralization of IL-6 with specific anti-IL-6 mAb showed
diminished corneal angiogenic responses as compared to control treated mice post HSV
infection (36, 37, 91).
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In addition to IL-1β and IL-6, IL-17 has been shown to exhibit pro-angiogenic
activity in different angiogenesis models (48, 49, 52). IL-17A signaling through the IL-17
receptor A induces the expression of a wide range of molecules such as VEGF-A, nitric
oxide, prostaglandins, colony stimulating factor (CSF) - 2, CSF-3, MIP-2, CXCL1 (KC),
CXCL2, CXCL-5, CXCL6, ICAM-1 and CCL2 by stromal fibroblast cells (48, 49, 52).
Additionally, IL-17 also increases the expression of IL-1β, IL-6 and TNF-α by fibroblasts
as well as monocytes (92, 93). Moreover, IL-17 was shown to play a direct role in
angiogenesis through increased migration and cord formation of vascular endothelial
cells in vitro as well as to increase the in vivo angiogenic response in a rat cornea assay
(94). Since, IL-17A expression is upregulated after HSV-1 infection (64, 65), it is
possible that IL-17A may contribute to HSV induced corneal angiogenesis. We analyzed
this possibility for the role of IL-17A in corneal angiogenesis post HSV infection and
results are described in chapter IV show that IL-17A promotes and orchestrates several
events critical for angioggeneis after HSV infection.

Conclusions
In summary, HSV infection of the cornea leads to the development of a complex
immunopathological reaction in cornea, termed as stromal keratitis. Clinically, SK
lesions are characterized by severe keratitis, necrosis, corneal opacity, as well as
development of new blood vessels in the normally avascular cornea. Pathogenesis of SK
involves several events such as viral replication, migration of cells of innate and adaptive
immune responses, increased expression of various cytokines and chemokines as well as
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angiogenic factors. Although, numerous past studies have elucidated the various
molecular events responsible for the development of complex immuno-inflammatory
lesions, mechanisms responsible for corneal angiogenesis, as well as the relative
involvement of different subsets of CD4+ T Cells in SK pathogenesis are poorly
understood.
The work described in this dissertation evaluated three important aspects of HSV
immunopathology that includes:
1)

Relative role of IL-17/IFN-γ and Th1/Th17 cells in HSV induced corneal
immunopathology. In this study we showed that SK immunopathology was the
outcome of a combined and sequential role of both Th1 and Th17 cells. Th1 cells
were HSV specific migrated initially during the early stages of clinical SK
followed by the migration of Th17 cells mostly of which were HSV non-specific.
IL-17A contributed to the SK immunopathology by promoting HSV induced
angiogenesis as well as increased infiltration of neutrophils. In contrast IFN-γ was
found protective during early the stages of SK pathogenesis, but was pathogenic
during the later stages when SK lesions were fully evident.

2)

Understanding the molecular mechanisms responsible for an imbalance between
VEGF-A and sVEGFR-1 and subsequent corneal angiogenesis post HSV
infection. We found that HSV infection of the cornea lead to an increased
expression of VEGF-A, but reduced sVEGFR-1 expression. In addition to
decreased expression of sVEGFR-1, we observed the degradation of sVEGFR-1,
which was primarily catalyzed by MMP-2, -7 and -9. Finally, we confirmed that
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neutrophils act as a source of additional VEGF-A as well as various sVEGFR-1
degrading MMPs.

3)

Role of IL-17A mediated effects on the balance between VEGF-A and sVEGFR1 in HSV induced corneal neovascularization. In this study, we showed that IL17A expression was increased after HSV infection. IL-17A through multiple
mechanisms contributed to the disruption of the inhibitory interaction between
VEGF-A and sVEGFR-1. IL-17A also promoted the expression of VEGF-A,
sVEGFR-1 degrading MMPs and CXCL1/KC a chemoattractant for neutrophils.
The net effect was increased VEGF-A levels along with a decrease of sVEGFR-1
with the outcome of corneal angiogenesis post HSV infection.

Collectively, data presented here have identified important aspects of HSV induced
corneal immunopathology, which can be exploited for better therapeutic management of
SK, an important cause of infectious blindness in the Western World.
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FIGURE 1.1 PRINCIPAL EVENTS IN HSV INDUCED CORNEAL SK PATHOGENESIS
Post HSV infection of the cornea, replicating virus is detectable in the cornea till day 7 pi.
Early after HSV infection, PMN, particularly neutrophils infiltrate the stromal layer of
cornea, and play an important role in virus clearance. Development of new blood vessels
from existing limbal vessels can be noted as early as day 1 pi. During clinical phase SK
lesions become evident which are characterized by the infiltration of lymphocyte,
particularly Th1 cells, neutrophils and the development of blood vessels.
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FIGURE 1.2 CLINICAL PHASE OF SK
Clinical phase of SK is marked by corneal infiltration of the T lymphocytes, particularly
CD4+ T lymphocytes and the development of new blood vessels in normally avascular
cornea.
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PART-II

ROLE OF IL-17 AND TH17 CELLS IN HSV
INDUCED CORNEAL
IMMUNOPATHOLOGY
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Research described in this chapter is a slightly modified version of an article that is
accepted for publication in Journal of Immunology by Amol Suryawanshi, Sachin Mulik,
Shalini Sharma, Pradeep BJ Reddy, Sharvan Sehrawat and Barry T Rouse.

Suryawanshi A, Veiga-Parga, Rajasagi N, Reddy PB, Sehrawat S and Rouse BT. Role of
IL-17 and Th17 Cells in HSV Induced Corneal Immunopathology. J. Immunol. 2011. 187
(4). Copyright © 2011 by The American Association of Immunologists, Inc.

In this chapter “our” and “we” refers to me and co-authors. My contribution in the paper
includes (1) Selection of the topic (2) Compiling and interpretation of the literature (3)
Designing experiments (4) Understanding the literature and interpretation of the results
(5) Providing comprehensible structure to the paper (6) Preparation of graphs and figures
(7) Writing and editing.

Abstract
Herpes Simplex Virus-1 (HSV) infection of the cornea leads to a blinding
immuno-inflammatory lesion of the eye termed stromal keratitis (SK). Recently, IL-17
producing CD4+ T cells (Th17) were shown to play a prominent role in many
autoimmune conditions, but the role of IL-17 and/or of Th17 cells in virus
immunopathology is unclear. Here we show that, after HSV infection of the cornea, IL17 is upregulated in a biphasic manner with an initial peak production around day 2 pi
and a second wave starting from day 7 pi with a steady increase until day 21 pi, a time
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point when clinical lesions are fully evident. Further studies demonstrated that innate
cells particularly, γδ T cells, were major producers of IL-17 early after HSV infection.
However, during the clinical phase of SK, the predominant source of IL-17 was Th17
cells which infiltrated the cornea only after the entry of Th1 cells. By ex-vivo stimulation,
the half fraction of IFN-γ producing CD4+ T (Th1) cells were HSV specific, whereas
very few Th17 cells responded to HSV stimulation. The delayed influx of Th17 cells in
the cornea was attributed to the local chemokine and cytokine milieu. Finally, HSV
infection of IL-17 receptor knockout mice, as well as IL-17 neutralization in WT mice
showed diminished SK severity. In conclusion, our results show that IL-17 and Th17
cells contribute to the pathogenesis of SK, the most common cause of infectious
blindness in the western world.

Introduction

Ocular infection with herpes simplex virus (HSV) can cause a chronic
inflammatory reaction in the corneal stroma that may culminate in blindness (1, 2). This
stromal keratitis (SK) lesion in humans is suspected to represent an immunopathological
reaction, a notion well supported by studies with animal models of SK (2-5). An
inevitable consequence of ocular HSV infection is life long latency in neuronal cells of
the trigeminal ganglion (6). In humans, periodic reactivation from some latently infected
cells give rise to replicating virus that acts as the most common stimulus for SK lesion
development (2-5). A major objective of SK research is to identify the role of cellular and
molecular events involved in tissue damage and its resolution with a view to improving
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current means of management of this often distressing disease. Studies in the mouse
models of SK have firmly established an essential role for T cells as the principal
orchestrators of SK lesions (7, 8). However, the actual tissue damage appearance to be
the consequence of inflammatory events that derive primarily from neutrophils that
represent the major cellular component of lesions at all phases of SK pathogenesis (9,
10). The prominence of neutrophils in SK lesions could indicate that the recently
identified proinflammatory cytokine IL-17 is a significant participant in the pathogenesis
of lesion development. Accordingly, IL-17 functions indirectly to cause tissue infiltration
by neutrophils, acts as a neutrophil survival factor and also may drive the cells to produce
and release tissue damaging molecules such as MMPs and oxyradicals (11-15).
In human SK, the presence of IL-17 has been reported (16). Additionally, the
Lausch group showed that the severity of early SK lesions were diminished in mice
unable to respond to IL-17 because they lacked the IL-17 receptor (17). However, the
cellular source of IL-17 as well as the role this cytokine plays compared to other
inflammatory mediators remains to be further defined. This is the topic of the present
communication.
We show that HSV infection of the cornea leads to the biphasic upregulation of
IL-17. Initially its source was innate cells that included γδ T cells, whereas later during the
clinical phase Th17 cells were the predominant producer. The CD4+ T cell subset
responsible for orchestrating SK appeared to be mainly Th1 cells at all stages of SK. On the
other hand, very few Th17 cells infiltrated into the cornea during early stages of SK (day 8
and 15 pi) but became more prominent during very late stage of SK (day 21 pi), when SK
lesions were fully evident. The late entry of Th17 cells was partly explained by the delayed
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upregulation of IL-6 and TGF-β, cytokines responsible for Th17 generation, as well as
CCL20 expression in the cornea, a chemokine responsible for the migration of Th17 cells
at the site of inflammation. On the basis of anti-cytokine suppression and comparison of
lesion severity between WT and IL-17 receptor knock out (IL-17RKO) mice, our result
show that IL-17 contributes to inflammatory events during the pathogenesis of SK. Future
therapies targeting the IL-17 response could be useful to alleviate the SK lesion severity, an
important cause of infectious blindness in humans.

Material and Methods

Mice, Virus and cell lines. IL-17RA -/- mice on C57B1/6 background were obtained
from Amgen Inc. (Thousand Oaks, CA, USA). C57BL/6 mice were purchased from
Harlan Sprague Dawley, Indianapolis, IN. Animals were housed in the animal facilities
approved by the Association for Assessment and Accreditation of Laboratory Animal
Care (AAALAC) at The University of Tennessee and all experimental procedures were in
complete agreement with the Association for research in Vision and Ophthalmology
resolution on the use of animals in research. HSV-1 RE Tumpey and HSV-KOS viruses
were grown in Vero Cell monolayers (ATCC no. CCL81, American Type Culture
Collection). The virus was concentrated, titrated, and stored in aliquots at -800 C until
use.
Corneal HSV Infection and Clinical Scoring. Corneal infections of mice were
conducted under deep anaesthesia induced by i.p. injection of avertin as previously
described (18). Mice were scarified on their corneas with 27-gauge needle, and a 3-µl
	
  

40	
  

drop containing 1×104 PFU of virus was applied to the eye. The eyes were examined on
different days pi for the development and progression of clinical lesion by slit-lamp
biomicroscope (Kowa Company, Nagoya, Japan). The progression of SK lesion severity
and angiogenesis of individually scored mice was recorded. The scoring system was as
follows: 0, normal cornea; +1, mild corneal haze; +2, moderate corneal opacity or
scarring; +3, severe corneal opacity but iris visible; +4, opaque cornea and corneal ulcer;
+5, corneal rupture and necrotizing keratitis. The severity of angiogenesis was recorded
as described previously (19). According to this system, a grade of 4 for a given quadrant
of the circle represents a centripetal growth of 1.5 mm towards the corneal center. The
score of the four quadrants of the eye were then summed to derive the neo vessel index
(range 0-16) for each eye at a given time point.
Reagents and Antibodies. CD4-allophycocyanin (RM4-5), IL-17-PE (TC11-18H10),
IFN- γ-FITC (XMG1.2), γδ TCR-FITC (GL3), anti-CD3 (145.2C11), anti-CD28 (37.51),
purified anti-IL-17, purified anti-IFN- γ and GolgiStop (Brefeldin A) were purchased
from BD Bioscience. Foxp3-PE, IL-17 and IFN- γ ELISA kit were purchased from
eBioscience. Anti γδ TCR (UC3-10A6) and Hamster IgG isotype control Ab were
purchased from Bio-X-Cell. PMA and ionomycin were purchased from Sigma-Aldrich.
γδ T cell Depletion. C57BL/6 mice were injected on day 2 before infection with 500
µg/mouse anti-mouse γδ TCR (clone UC3-10A6) followed by 250 µg/mouse on day of
infection.
Sub‐conjunctival Injection. Subconjunctival injections of anti-IL-17 were performed as
described previously (20). Briefly, subconjunctival injections were done using a 2 cm,
32 gauge needle and syringe (Hamilton, Reno, NV) to penetrate the perivascular region
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of conjunctiva, and the required dose of anti-IL-17 mAb

was delivered into

subconjunctival space. Control mice received isotype mAb.
IL-17 and IFN-γ Neutralization. C57BL/6 mice were ocularly infected and 0.05 mg of
anti-IL-17 or anti-IFN- γ was given intraperitoneally (i.p.) starting from day -1 followed
by day 2 and day 5 pi or starting from day 7 followed by day 10 and 13 pi. For local
depletion, 5 µg anti-IL-17 mAb was administered by sub-conjunctival injection following
same regimes as described above.
Isolation of corneal-infiltrating cells and flow cytometry. HSV infected corneas were
harvested from different group of mice at indicated time point pi. Six to eighth corneas
per group were excised, pooled group wise, and digested with 60 U/ml Liberase for 35
minutes at 370C in a humified atmosphere of 5% CO2. After incubation, the corneas were
disrupted by grinding with a syringe plunger on a cell strainer and single-cell suspensions
were made in complete RPMI 1640 medium. The single cell suspensions obtained from
corneas, DLNs and spleen were stained for different cell surface molecules for FACS. All
steps performed at 40C. Briefly, cell suspension were first blocked with an unconjugated
anti-CD32/CD16 mAb for 30 min in FACS buffer. After washing with FACS buffer,
samples were incubated with CD4-APC (RM4-5) for 30 min on ice. Finally, the cells
were washed three times and re-suspended in 1% para-formaldehyde.
To measure the number of IFN-γ, IL-17 and IL-2 producing CD4+ T cells,
intracellular cytokine staining was performed. Briefly, 106 freshly isolated cells from
DLNs, spleens or corneas were left untreated or stimulated with PMA plus ionomycin
along with GolgiStop for 4 hrs at 370C in 5% CO2. To quantify IL-2 producing CD4+ T
cells, cells were stimulated with anti-CD3 (1ug/ml) and anti-CD28 (0.5 ug/ml) for 5 hrs
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in the presence of GolgiStop at 370C in 5% CO2. To enumerate the HSV-specific Th1 and
Th17 cells, cells were stimulated with 2 multiplicity of UV-inactivated HSV and
incubated overnight at 370C in 5% CO2. GolgiStop (10mg/ml) was added for the last 5
hrs of the stimulation. At the end of stimulation period, cell surface staining was
performed as described above, followed by intracellular cytokine staining using
Cytofix/Cytoperm kit (BD Pharmingen) in accordance with the manufacturer’s
recommendations. FITC labeled IFN-γ and PE labeled IL-17 antibodies were used. After
final washing cells were resuspended in 1% para-formaldehyde. The stained samples
were acquired with a FACS Calibur (BD Biosciences) and the data were analyzed using
the FlowJo software.
Quantitative PCR (QPCR). Corneal cells were lysed and total mRNA was extracted
using TRIzol LS reagent (Invitrogen). Total cDNA was made with 500 ng of RNA using
oligo(dT) primer. Quantitative PCR was performed using SYBR Green PCR Master Mix
(Applied Biosystem, Foster City, CA) with iQ5 real-time PCR detection ssystme (Bio
Rad, Hercules, CA). The expression levels of different molecules were normalized to βactin using ΔCt calculation. Relative expression between control and experimental groups
were calculated using the 2-ΔΔCt formula. The PCR primers used were as follows
β

ACTIN-

For

5’-TCCGTAAAGAATCTCATGCC-3’,

Rev

5'-

ATCTTCATCCTCCTAGGAGC-3'; IFN-Υ For 5’-GGATGCATTCATGAGTATTGC3’,

Rev

5’-GCTTCCTGAGGCTGGATTC-3’;

IL17A

For

5’-

GCTCCAGAAGGCCCTCAG-3’, Rev 5’- CTTTCCCTCCGCATTGACA-3’; IL6- For
5’-

CGTGGAAATGAGAAAAGAGTTGTGC-3’,

ATGCTTAGGCATAACGCACTAGGT-3’
	
  

43	
  

TGFβ-For

Rev

5’5'-

TTGCTTCAGCTCCACAGAGA-3’, Rev 5’- TGGTTGTAGAGGGCAAGGAC-3’;
CCL20

-

For

5’-GCCTCTCGTACATACAGACGC-3’,

Rev5’-

CCAGTTCTGCTTTGGATCAGC-3’.
ELISA. The pooled corneal samples were homogenized using a tissue homogenizer and
supernatant was used for analysis. The concentrations of

IL-17A and IFN-γ were

measured by using sandwich ELISA kits (eBioscience) as per the manufacturer’s
instructions.
Statistics. Student’s t test was performed to determine statistical significance and data are
expressed as mean ± SEM.

Results

IL-17 is up-regulated in the cornea of mice ocularly infected with HSV-1
Total mRNA isolated from the corneas of HSV infected mice was analyzed for
the relative fold changes in IL-17 mRNA expression by RT-PCR. As is evident in Figure
2.1A, the expression profile revealed that IL-17 was upregulated in a biphasic manner.
During the early phase, IL-17 expression was elevated at day 2 pi, but returned to near
basal levels around day 5 pi. This was followed by a subsequent upregulation of IL-17
starting from day 7 pi with a steady increase until day 21 pi (last observed time point),
which corresponds to the chronic phase of the disease. In addition, quantification of IL17 by ELISA revealed a similar pattern of expression as observed with RT-PCR (Figure
2.1B). Early after HSV-1 infection, innate cells infiltrate the cornea, and CD4+ T cells
start infiltrating the infected cornea around day 7p.i. (1). Recent studies have implicated
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innate cells, particularly γδ T cells as one of the major sources of IL-17 (21-25).
Therefore to investigate this possibility in our system, IL-17 producing γδ T cells were
enumerated by intracellular cytokine staining (ICCS) after stimulation with
PMA/ionomycin. Around 16% of total γδ T cells produced IL-17 (Figure 2.1C), and
depletion of γδ T cells using a specific monoclonal antibody diminished the levels of IL17 as measured by ELISA (Figure 2.1D). Collectively, these data show that IL-17
expression is upregulated in a biphasic manner following HSV infection and innate γδ T
cells contribute to the early source of IL-17.

Th1 cells predominate during early stages of SK pathogenesis followed by Th17 cells
in later stages.
Past studies showed that CD4+ T cell infiltration of the corneal stroma becomes
readily apparent by 7 day pi (1, 7, 8), but the relative composition of the CD4+ T effectors
was not recorded. Using the intracellular cytokine staining approach with cells isolated
from collagen digested pooled corneas, the relative frequencies of Th17 and Th1 cells
were measured in the HSV infected corneas at day 8, 15 and 21 pi. As shown in Figure
2.2A, stimulation of corneal cells with PMA and ionomycin revealed a large proportion
of CD4+ T cells producing either IFN-γ or IL-17 within the corneal infiltrate. However,
the ratio of frequencies of Th1 to Th17 were higher at all tested time point pi.
Additionally, Th1 cells showed an initial increase at day 15 over day 8 pi followed by
reduced frequencies at day 21 pi. In contrast to Th1 cells, Th17 cells were scarcely
detectable on day 8 pi and this was followed by a gradual increase in their frequency with
the progression of SK (Figure 2.2A). The total cell numbers for each population revealed
	
  

45	
  

similar kinetics (Figure 2.2B, middle column). Furthermore, intracellular staining of
corneal cells stimulated with UV inactivated viral antigen preparation revealed a high
percentage (≤ 24.4 %) HSV specific Th1 cells as compared to a lower percentage (≤ 0.35
%) of HSV specific Th17 cells (Figure 2.2A right column). In addition, analysis of local
draining lymph nodes (DLN) for Th1 and Th17 cells, revealed a similar pattern as
observed for the cornea (Figure 2.2 C, D). These results indicate Th1 cells initially
infiltrate the site of infection followed by the increased infiltration of Th17 cells during
late stages of SK.

Local cytokine/chemokine directs delayed entry and/or differentiation of Th17 cells
in the cornea.
The delayed migration of Th17 cells in the cornea could be the result of the early
conditions suppressing Th17 cells or conditions such as local cytokine and chemokine
milieu favoring Th17 cell generation and/or migration during later stages of SK. To
further investigate this issue, studies were carried out for the corneal quantification of
different cytokines as well as chemokines, particularly those that are involved in the
generation, migration and suppression of Th17 cell responses.

Since Th17 cells

differentiate from naïve CD4+ T cell in the presence of IL-6 and TGF-β with antigenic
stimulation (26-28), we quantified the relative fold change of IL-6 and TGF-β at various
days pi as compared to mock infected cornea (Figure 2.3 A and 2.3 B). The results
showed relatively low levels of IL-6 at day 8 pi followed by a peak at day 15 pi. (Figure
2.3A). TGF-β levels were upregulated from day 8 pi and, peaked at day 15 pi. As
compared to day 15 pi, both IL-6 and TGF-β levels were reduced by day 21 pi.
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Furthermore, quantification of CCL20 a known ligand for CCR6, which is preferentially,
expressed by homeostatically proliferating Th17 cells as well as Treg cells (29, 30), was
significantly expressed only after day 15 pi (Figure 2.3C). Furthermore, since a recent
study has shown the suppressive role of IL-2 in the generation of Th17 cells (31), we
quantified CD4 T cells producing IL-2 in the local DLN and spleen by ICCS assay. As
shown in Figure 2.3D-E, IL-2 producing CD4+ T cells were significantly higher in
frequency as well as numbers at day 8 pi followed by a reduction at day 15 and day 21 pi.
This early and robust IL-2 production by CD4+ T cells could be responsible for the
promotion of Th1 as well as the suppression of Th17 responses in lymphoid organs early
after HSV infection. However, during the progression of SK, increased IL-6, TGF-β as
well as chemokine CCL20 expression in the cornea could be responsible for either
generation or migration of Th17 cells during the later stages of SK.

The Dual Role of IFN-γ in HSV induced immunopathology
Since, IFN- γ suppresses the induction and expansion of Th17 cells (17, 32-34),
we investigated the role of IFN-γ in relation to IL-17 as well as Th-17 cells. Similar to
IL-17, IFN-γ showed biphasic upregulation. However, the second peak expression was
observed around day 7 pi followed by a steady decline with the progression of SK
(Figure 2.4A). Measurement of IFN-γ cytokine by ELISA revealed similar kinetics of
expression as observed with QPCR analysis (Figure 2.4B). To demonstrate the role of
IFN-γ in SK, IFN-γ depletion was carried out from day -1 followed by depletion on day 2
and day 5. The severity of SK lesions was scored on day 8 and day 11. As shown in
figure 2.4C, early depletion of IFN-γ significantly increased the severity of SK on day 8.
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However, on day 11 it reached that of isotype antibody treated control mice group.
Furthermore, all mice from IFN- γ depleted group showed signs of severe encephalitis,
which necessitated termination of experiments. In contrast, depletion of the second peak
of IFN-γ during later stages of SK (on day 7, 10 and 13) showed significantly diminished
SK lesion severity on day 11 and day 15 pi (Figure 2.4D). The analysis of various cell
types from the corneas showed reduced frequencies of total CD4+ T cells, the Th1 subset,
but increased percentage of the Th17 subset (Figure 2.4E-F). However, the total numbers
of total CD4+ T cells, Th1 and Th17 cells were reduced in IFN-γ depleted mice as
compared to isotype treated antibody treated mice. These results demonstrate an early
protective role of IFN-γ likely acting by controlling virus replication in cornea. However,
IFN-γ exerts a pathologic role once virus is cleared from the cornea as occurs during the
later stages of SK. Taken together, our data indicates that Th1 cells are the initial main
orchestrators of SK lesions followed later on in the chronic phase by the contribution of
both Th1 and Th17 cells. Early infiltration of Th1 cells initiates the inflammatory
condition particularly cytokines and chemokine environment that promotes generation
and/or migration of highly pathogenic Th17 cells. This late migration of Th17 cells
maintains the SK pathology via their secretion of IL-17, which acts as a proinflammatory cytokine through various mechanisms.

IL-17 neutralization diminishes SK lesion severity.
To further investigate the role of IL-17 in SK pathogenesis, the effects of
neutralizing IL-17 with monoclonal Ab was studied over a 15 day observation period.
Intraperitoneal Treatment was began on 1 day before infection followed by injections on
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day 2 and day 5 pi. The early neutralization of IL-17 reduced the SK lesion severity on
day 11 pi (Fig 2.5A). To further confirm the role of IL-17 during later stages of SK, IL17 neutralization was started from day 7 pi when SK lesions become evident, followed by
depletion on day 10 and 13 pi. This therapeutic neutralization of IL-17 also reduced the
severity of SK lesions further confirming the pathogenic role of IL-17 during the later
stages of SK (Fig 2.5B). In addition, therapeutic local depletion of IL-17 by
subconjunctival administration of anti-IL-17 antibody also resulted in significantly
diminished SK lesion scores (Fig 2.5C). Examination of corneal sections by
histopathological analysis revealed reduced inflammatory response in the IL-17 depleted
corneas, with less fibrosis of corneal stroma, no or minimal hypertrophy of epithelial
layers as well as diminished infiltration of leukocytes, particularly neutrophils (Fig 2.5D).
Moreover, the frequencies as well as total numbers of CD4+ T cells, Th1 and Th17 cells
were also reduced in the anti-IL-17 treated group (Fig 2.5E-F). The reduced numbers of
Th1 cells could be the result of reduced infiltration of neutrophils, which may act as a
source of CXC chemokines essential for Th1 infiltration (35). Taken together, these data
indicated the pathogenic role of IL-17 during early as well as late phases of SK.

IL-17R KO mice show reduced SK lesion severity.
To further confirm the role of IL-17 in SK pathogenesis, mice lacking IL-17
receptor signaling were ocularly infected with HSV and SK lesion severity was
monitored and compared with WT mice. The disease severity differed significantly at all
tested time point pi between WT and IL-17R KO mice (Fig 2.6A). The onset of SK was
delayed and SK lesions were less severe in IL-17R KO, as compared to their WT
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counterparts. The severity of SK lesions (scores of ≥3) was reduced in mice in the IL-17R
KO group (3 of 8 eyes at day 21) compared to WT counterparts (7 of 8 eyes at day 21)
(Fig 2.6A right panel). Furthermore, histopathological analysis of WT corneas at day 15
pi showed loss of the corneal epithelial layer, extensive stromal fibrosis, infiltration of
large number of leukocytes in the stromal layers with the resultant thickening of corneal
stroma (Fig 2.6B, upper panels). In contrast to WT corneas, section from IL-17R KO
corneas showed no damage to the epithelial layer with minimal fibrosis as well as
infiltration by inflammatory leukocytes at day 15 pi (Fig 2.6B lower panels). Moreover,
immunofluorescence staining of corneal sections for CD4+ T cells at day 15 pi showed
diminished infiltration of CD4+ T cells in IL-17R KO mice as compared to WT mice
(Figure 2.6C). To further quantify the different cell types infiltrating the cornea,
experiments were terminated on day 15 to study cellular parameters. As shown, the
frequencies (Fig 2.6D-F) and absolute numbers (Fig 2.6G) of total CD4+ T cells, Th1 and
Th17 cells were decreased in the IL-17R KO compared to WT mice. Additionally, the
expression of pro-inflammatory cytokines such as IL-6, IL-17, IL-1β were diminished in
IL-17R KO mice corneas as compared to the WT samples (data not shown). Analysis of
DLN and spleen of WT and IL-17R KO, mice showed reduced frequencies, but not total
cell numbers of each population (Fig 2.7). As shown in Figure 7A-D, the frequencies of
Th1 and Th17 cells showed two fold reduction in DLNs and spleen from IL-17R KO
mice as compared to WT mice. However, the total numbers of each subpopulation were
equal in both IL-17R KO and WT mice DLNs and spleen (Fig 2.7E and F). These
observations revealed that although, the total cell numbers were equal in DLNs and
spleens from IL-17R KO and WT mice, the frequencies and total cell numbers were
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reduced at the inflammatory site (cornea) in IL-17R KO mice as compared to WT
counterparts. Taken together, these results indicated the pro-inflammatory role of IL-17
in SK pathogenesis

Discussion
In this study we show that HSV infection of the cornea leads to a biphasic
increase in corneal expression of IL-17. Moreover, the subsequent HSV induced SK
immunopathology is the outcome of the effector functions mediated by both Th1 and
Th17 cells. The pro-inflammatory cytokine IL-17 drives initial as well as late events in
SK pathogenesis and also contributes significantly to the pathology of SK. However, the
sources of IL-17 during early and late stages of SK were different. Initially, innate cells
such as γδ T cells were the main producers and later on in the chronic phase Th17 cells
were the producers. Additionally, IFN-γ was shown important for the early protection
from HSV infection, but cells producing IFN-γ also contributes to the pathology once the
virus is absent. Furthermore, HSV induced immunopathological lesions involve both
Th1 and Th17 cells with their respective importance changing with time. Accordingly, in
line with previous published reports, our data demonstrates that Th1 cells mainly initiate
and orchestrate SK lesions at least during the early stages followed by the entry of Th17
cells when the disease is at peak. Interestingly, significant proportion of Th1 cells
secreted IFN- γ upon stimulation with UV inactivated HSV virus, but most Th17 cells
failed to produce IL-17 under similar conditions, indicating that Th17 cells could be
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involved in a bystander fashion in SK pathogenesis. Furthermore, depletion of IL-17
during both early as well as during the chronic phase of SK pathogenesis and infection of
IL-17R KO mice showed reduced SK lesion severity. The findings indicate an important
role for IL-17 at all stages of SK pathogenesis. Accordingly targeting IL-17 production
represents a logical target to control SK, an important cause of human blindness.
Innate cells such as γδ T cells act as one of the major early sources of IL-17, as
shown in some other systems (21-25). Thus our data is in line with the previously
published reports where γδ T cells were shown to be main source of innate IL-17 (21-25).
IL-17 orchestrates the local inflammatory response by stimulating epithelial, endothelial
and fibroblastic cells to produce and release various inflammatory cytokines (12, 36-39).
Furthermore, IL-17 drives increased influx, as well as survival, of neutrophils at the site
of inflammation by the induction of neutrophil chemoattracts, as well as GM-CSF
mediated granulopoeisis (12, 39-41). In ocular HSV infection, an initial influx of
neutrophils plays an important role in virus clearance (42). The diminished expression of
neutrophil chemoattractants for neutrophils and subsequent reduced infiltration of
neutrophils occurs in IL-17R KO mice post HSV infection (17). Similarly, we found a
reduced infiltration of neutrophils in HSV infected IL-17R KO mice as well as post IL-17
neutralization during early as well as during late stages of SK pathogenesis (data not
shown). Taken together, the data show that during HSV infection of the cornea, IL-17
contributes to the early innate cell response by promoting the migration of neutrophils.
Recent work has discovered a critical role of Th17 cells in various chronic and
autoimmune inflammatory conditions (33, 34, 43-45), and our data show that Th17 cells
do participate in SK pathogenesis. However, in contrast to autoimmune as well as some
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chronic inflammatory conditions, where Th17 cells may play a dominant role, HSV
induced immunopathology results from the participation of both Th1 and Th17 cells with
the relative importance changing as disease progresses. Accordingly, our data from IFN-γ
and IL-17 neutralization as well as IL-17R KO mice shows that both Th1 and Th17
mediated immune response contributes to SK pathogenesis. Th1 cells were the first to
infiltrate the cornea, and significant proportions of them were HSV-specific. They set the
stage for the development of complex SK lesions that additionally involves Th7 cells.
However, the Th17 cells could migrate only after the entry of Th1 cells, indicating their
role in the later stages of SK. Our data accord with a recent study showing that only Th1
cells could gain entry in the non-inflamed tissue and initiate inflammatory response
followed by entry of Th17 cells in the inflamed CNS (46). Furthermore, almost none of
the Th17 cells responded to HSV specific antigen when stimulated ex-vivo which may
indicate their bystander role in SK pathogenesis. However, diminished SK severity in the
absence of IL-17 receptor signaling, as well as post IL-17 neutralization during early as
well as late stages of SK, indicated that IL-17 does play a pro-inflammatory role in SK
pathogenesis.
Although, presently we cannot detect the antigen specificity of these Th17 cells,
they could be reactive against yet unidentified unmasked self-corneal antigens or be
functioning in a bystander fashion. A recent study on an autoimmune condition of the
retina using experimental autoimmune uveitis model, showed that both the retinal antigen
specific Th1 and Th17 cells could drive autoimmunity depending upon the local
conditions at the time of antigen exposure as well as type of T effector cell present (47).
However, our data show that during viral immunopathology, higher levels of IFN-γ occur
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early after HSV infection could promote Th1 and suppress Th17 immune responses.
During autoimmune conditions exposure of self-unmasked antigens occur that provides
constant stimulation to the T effector cells at the site of inflammation (48). The body
might sense this chronic persistence of antigen as the need arises for stronger and more
pathogenic immune response for the removal of such persistent antigen. The highly
pathogenic nature of IL-17 and or Th17 cells meets this criterion and might be the
outcome of such persistent antigenic stimulation as observed in many autoimmune
conditions. However, during acute infections, effective Th1 and Th2 responses could
clear the antigen from the site of infection, avoiding the Th17 mediated
immunopathology. In contrast, chronic persistence of antigen could be sensed by the
body, with a resultant robust T effector response such as a Th17 cell mediated immune
response, which can cause damage and subsequent immunopathology. SK, being a
chronic disorder could mimic this condition, where initial acute viral infection is
controlled by the Th1 cell response that initiates inflammatory milieu in the cornea. This
initial damage to the corneal tissue could uncover self-antigens that help drive the
subsequent Th17 mediated highly inflammatory reaction. Alternatively, one recent study
showed that Th17 cells can be activated in the context of the local microenvironment and
could cause tissue specific damage in an antigen non-specific way that depended upon
the presence of IL-6 (49). Thus, it might be possible that these Th17 cells during late
stages of SK could be non-specific to the corneal Ag and acting in a bystander fashion
stimulated in the presence of the complex inflammatory cytokine milieu. However, this
issue needs to be addressed further using adoptive transfer of non-specific Th17 cells in
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the context of HSV induced SK immunopathology. Such studies are currently undergoing
in our laboratory.
Our data also demonstrates a dual role of IFN-γ during HSV mediated
immunopathology. Innate cells contribute to the early source of IFN-γ after HSV
infection and Th1 cells from day 7 pi (1, 50). Thus, IFN-γ neutralization during the preclinical phase when replication virus is still present in cornea (1), lead to the transient
increased tissue damage presumably driven by virus. Furthermore, this early depletion
caused severe encephalitis, possibly an effect of higher viral titers indicating the early
protective role of IFN-γ as previously documented (1, 49, 51). Interestingly,
neutralization of IFN-γ after day 7 pi resulted in significantly reduced SK severity
indicating a crucial role of IFN-γ and/or Th1 cells as the initiators and main orchestrators
of early immunopathological lesions of SK. Since, IL-2 and IFN-γ suppresses Th17
response (17, 31-34), conceivably during HSV induced immunopathology higher levels
of IFN-γ in the cornea could be suppressing the early development of Th17 responses.
Furthermore the chronic inflammatory situation in the cornea might be creating
appropriate conditions for the generation and or migration of Th17 cells. Naïve CD4+ T
cells differentiate into Th17 cells under appropriate antigenic stimulation in the presence
of IL-6 and TGF-β (26-28). Furthermore, Th17 cells express the chemokine receptor,
CCR6, and migrate to the site of inflammation through the specific chemokine, CCL20
(29, 30). Indeed, our data for the expression levels of IL-6, TGF-β and CCL20 indicated
that conditions favored either migration and/or generation of Th17 cells occur only
during the very late stage of SK pathogenesis. This might explain the delayed appearance
of Th17 cells in the cornea.
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Taken together, our results demonstrate the relative contribution of IL-17/Th17 and IFNγ/Th1 cells in the pathogenesis of SK. Both cell types participate in the pathogenesis of
SK depending on the stage of SK. The demonstration of the pathogenic role of IL17/Th17 cells in later stages of SK is a novel finding and could have implication for
future therapeutic intervention for HSV induced immunopathology, an important cause of
infectious human blindness.
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FIGURE 2.1. IL-17 EXPRESSION IS UPREGULATED IN THE HSV INFECTED CORNEA AND
INNATE CELLS CONTRIBUTE TO THE EARLY SOURCE OF IL-17.

C57BL/6 mice were ocularly infected with 1X 10

4

PFU of HSV. Control mice were

mock infected with PBS. At each time point 6 corneas were collected and pooled for
measurement of IL-17 levels by RT-PCR, ELISA or ICCS assay. (A-B) The kinetic
analysis for the expression of IL-17 in the HSV infected cornea as determined by RTPCR (A) and ELISA (B). The expression levels of IL-17 by RT-PCR at various time
points were quantified relative to β-actin using ΔΔCT method. (C) On day 2 pi, corneas
were collected and analyzed by ICCS assay for the production of IL-17 by γδ T cells.
Cells were stimulated with PMA/Ionomycin for 4 hrs in the presence of Brefeldin A. (D)
The IL-17 levels at day 2 pi in γδ T cell depleted C57BL/6 mice as determined by
ELISA. Animals in the control group received isotype antibody. Data are shown for one
representative experiment out of two with 6 to 8 mice at each indicated time point pi.
Statistical levels of significance were analyzed by Student’s t test. Error bars ar
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FIGURE 2.2. KINETIC ANALYSIS OF TH1 AND TH17 CELLS IN THE CORNEA AND DLN OF
HSV INFECTED MICE.
C57BL/6 mice were ocularly infected with 1X 10 4 PFU of HSV and each time
point 6 to 8 corneas were collected, pooled and liberase digested. The corneal single cell
suspensions were analyzed for the CD4+ T cell expression of IL-17 and IFN-γ by ICCS
assay. (A) Representative FACS plots for the corneal Th1 and Th17 cells at each time
point pi. The cells were either un-stimulated (left column) or stimulated with
PMA/Ionomycin for 4 hrs (middle column) in the presence of Brefeldin A. For
quantification of Ag-specific CD4+ T cells (right panel), cells were stimulated for 16 hrs
with UV-inactivated HSV-KOS, with the addition of Brefeldin A for last 5 hrs of
stimulation. FACS plots shown are gated on CD4+ T cells. The ratio shown on the right
side is a comparison of PMA/Ionomycin stimulated Th1 to Th17 cells on respective day
pi. (B) Total number Th1 and Th17 cells per cornea at day 8, 15 and 21 pi by ICCS assay
post stimulation with PMA/Ionomycin. (C) Representative FACS plot for Th1 and Th17
cells from the local DLN of HSV infected mice at day 8, 15 and 21 pi. The cells were
either un-stimulated or stimulated with PMA/Ionomycin for 4 hrs or with UV-HSV-KOS
for 16 hrs. (D) Frequencies and total numbers (E) of Th1 and Th17 cells from DLN at
day 8, 15 and 21 pi as determined by ICCS assay post stimulation with PMA/Ionomycin.
Data are shown for one representative experiment out of two with 6 to 8 mice at each
indicated time point pi. Statistical levels of significance were analyzed by Student’s t test.
Error bars are SEM.
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FIGURE 2.3. DELAYED EXPRESSION OF IL-6, TGF-Β AND CCL20 ALONG WITH
+

REDUCED IL-2 EXPRESSION BY CD4

T CELLS DIRECTS THE DELAYED GENERATION

AND/OR ENTRY OF TH17 CELLS.

C57BL/6 mice were ocularly infected with 1X 10

4

PFU of HSV. Control mice were

mock infected with PBS. Mice were sacrificed on day 8, 15 and 21 pi and corneas, local
DLN and spleen were collected for the analysis by RT-PCR and ICCS assay. (A-C) At
each time point 6 corneas were collected and pooled for the measurement of IL-6 (A),
TGF-β (B) and CCL20 (C) levels by RT-PCR. The expression levels of different
molecules were quantified relative to β-actin using ΔΔCT method. The IL-2 producing
CD4+ T cells were analyzed by ICCS assay as described in materials and methods.
Representative FACS plots (D) and total cell numbers (E) for IL-2 producing CD4+ T
cells from the DLN and spleen at day 8, 15 and 21 day pi. Cells are gated on CD4+ T
cells. Data are shown for one representative experiment out of two with 6 mice at each
indicated time point pi. Statistical levels of significance were analyzed by Student’s t test.
Error bars are SEM.
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FIGURE 2.4. EARLY PROTECTIVE AND LATE PATHOLOGIC ROLE OF IFN-Γ IN SK
C57BL/6 mice were ocularly infected with 1X 10 4 PFU of HSV. Control mice
were mock infected with PBS. At each time point 6 corneas were collected and pooled
for measurement of IFN- γ levels by RT-PCR, ELISA or for analysis by ICCS assay. (AB) The kinetic analysis for the expression of IFN-γ in the HSV infected cornea as
determined by RT-PCR (A) and ELISA (B). The expression levels of IFN-γ by RT-PCR
at various time points were quantified relative to β-actin using ΔΔCT method. (C-D)
Diminished SK lesion severity in mice treated with anti-IFN- γ as compared to isotype
Ab treated mice. Group of 2 to 4 mice were treated i.p. with anti-IFN- γ on either starting
from day -1, followed by treatment on day 2 and day 5 pi (C); or either starting from day
7 pi followed by treatment on day 10 and 13 pi (D). Mice in control group received
isotype control Ab. (E-H) Mice from experiment (D) were sacrificed on day 15 pi and
corneas were collected for the analysis of different cell population by flow cytometry.
Representative FACS plots for total corneal infiltrating CD4+ T cells (E) and Th1 and
Th17 cells after stimulation with PMA/Ionomycin (F) from isotype and anti-IFN-γ
treated groups. (G) Total cell number per cornea for CD4+ T cells, Th1 and Th17 cells
shows reduced infiltration of cells in the cornea after IFN-γ neutralization. Data are a
representative summary of two independent experiments. Statistical levels of significance
were analyzed by Student’s t test. Error bars are SEM.
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FIGURE 2.5. IL-17 NEUTRALIZATION DIMINISHES SK LESION SEVERITY.
C57BL/6 mice ocularly infected with 1X104 PFU of HSV were divided into two groups
each with 6 to 8 mice. One group of mice received antibody against IL-17 and mice in
control group were administered with isotype antibody. (A-C) Diminished SK lesion
severity in mice treated with anti-IL-17 mAb. SK lesion score for individual cornea on
day 15 pi (right) are shown. (A) Early neutralization of IL-17 was carried by i.p. injection
of anti-IL-17 mAb from day -1 followed by day 2 and 5 pi. (B) Late neutralization of IL17 was carried by i.p. injection of anti-IL-17 mAb from day 7 followed by day 10 and 13
pi. (C) Local depletion of IL-17 was carried by sub-conjunctival delivery of anti-IL-17
using same strategy as that of late depletion. (D) Representative H&E stained corneal
sections of isotype treated (top panel) and IL-17 depleted (bottom panel) mice collected
on day 15 pi from experiment B. The figure shows the pictures of the section taken at X
10 (left), X 20 (middle) and X 100 (right) of original magnification. (E-F) Mice from late
depleted groups (as shown in B) were sacrificed on day 15 pi and corneas were harvested
and pooled group wise for the analysis of various cell types (n = 6-8 per group) by flow
cytometry. Representative FACS plot for total corneal infiltrating Th1 and Th17 cells (E)
from isotype and anti-IL-17 treated groups. (F) Total cell number per cornea for CD 4+ T
cells, Th1, Th17 cells shows reduced infiltration of cells in the cornea after IL-17
neutralization. Data are a representative summary of two independent experiments.
Statistical levels of significance were analyzed by Student’s t test. Error bars are SEM.
Statistical levels of significance were analyzed by Student’s t test. Error bars are SEM.
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FIGURE 2.6. IL-17R KO MICE ARE RESISTANT TO SK.
C57BL/6 and IL-17R KO mice were infected with 1X104 PFU of HSV. (A) The
disease progression kinetics and SK severity was assessed on day 8, 11, 15 and 21 pi (left
panel). Right panel shows the score of individual eye on day 15 pi (B) Representative
H&E stained corneal sections from WT (upper row) and IL-17R KO (lower row) mice
collected on day 15 pi. The figure shows the pictures of the section taken at X 10 (left), X
20

(middle)

and

X

100

(right)

original

magnification.

(C)

Representative

immunofluorescence micrograph of corneas for CD4+ T cells (green) from WT and IL17R KO mice on day 15 pi. The sections were counterstained with propidium iodide
(red). Scale bars, 75µm. Mice were sacrificed on day 15 pi and corneas were harvested
and pooled group wise for the analysis of various cell types (n = 6-8 per group). (D)
Representative FACS plots for corneal infiltrating total CD4+ T cells. (E) Intracellular
staining was conducted to quantify Th1 and Th17 cells by stimulating them with
PMA/Ionomycin (top) and HSV-KOS virus (bottom). (F) The bar diagram shows the
average frequencies of Th1 and Th17 cells after stimulation with PMA/ionomycin or UV
inactivated HSV-KOS from two independent experiments. (G) The bar diagram is a
summary for total numbers of corneal infiltrating CD4+ T cells, IFN-γ+ CD4+ T cells,
HSV stimulated IFN- γ+ CD4+ T cells, IL-17+ CD4+ T cells, HSV-Stimulated IL-17+
CD4+ T cells in the corneas of WT and IL-17R KO mice. Data are shown as a summary
of two independent experiments with 6 to 8 mice per group.

Statistical levels of

significance were analyzed by Student’s t test. *< 0.05; ***< 0.001. Error bars are SEM.
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FIGURE 2.7. IL-17R KO MICE EXHIBIT REDUCED FREQUENCIES BUT NOT NUMBERS OF
TH1 AND TH17 CELLS IN DLN AND SPLEEN POST HSV INFECTION.
C57BL/6 and IL-17R KO mice were infected with 1X104 PFU of HSV. Mice
were sacrificed on day 15 pi and single cell suspensions of the individual spleen and
draining cervical lymph nodes (DLN) were prepared. (n = 4). (A) Representative FACS
plots for Th1 and Th17 cells stimulated with PMA/Ionomycin (top) or HSV-KOS virus
(bottom). (B, C) Summary for average frequencies of different CD4+ T cell types as
depicted in A from DLN (B) and spleen (C). (D, E) The total numbers of IFN-γ+ CD4+ T
cells, HSV stimulated IFN- γ+ CD4+ T cells, IL-17+ CD4+ T cells, HSV-Stimulated IL17+ CD4+ T cells and Foxp3+ CD4+ T cells from DLN (D) and spleen (E) of WT and IL17RKO mice.
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PART-III
AN IMBLANCE BETWEEN VEGF-A AND
sVEGFR-1 MEDIATES CORNEAL
NEOVASCULARIZATION AFTER HSV-1
OCULAR INFECTION

	
  

81	
  

Research described in this chapter is a slightly modified version of an article that is
accepted for publication in Journal of Immunology by Amol Suryawanshi, Sachin Mulik,
Shalini Sharma, Pradeep BJ Reddy, Sharvan Sehrawat and Barry T Rouse.

Suryawanshi A, Mulik S. Sharma S, Reddy PB, Sehrawat S and Rouse BT. Ocular
neovascularization caused by herpes simplex virus type 1 infection results from
breakdown of binding between vascular endothelial growth factor A and its soluble
receptor.

J Immunol. 2011. 186, 3653-3665. Copyright © 2011 by The American

Association of Immunologists, Inc.

In this chapter “our” and “we” refers to me and co-authors. My contribution in the paper
includes (1) Selection of the topic (2) Compiling and interpretation of the literature (3)
Designing experiments (4) Understanding the literature and interpretation of the results
(5) Providing comprehensible structure to the paper (6) Preparation of graphs and figures
(7) Writing and editing.

Abstract
The normal cornea is transparent which is essential for normal vision and
although the angiogenic factor VEGF-A is present in the cornea, its angiogenic activity is
impeded by being bound to a soluble form of the VEGF receptor-1 (sVEGFR-1 or sVR1). This report investigates the effect on the balance between VEGF-A and sVEGFR-1
that

occurs

following

ocular

infection

with

HSV,

that

causes

prominent

neovascularization, an essential step in the pathogenesis of the vision-impairing lesion,
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stromal keratitis (SK). We demonstrate that HSV-1 infection causes increased production
of VEGF-A, but reduces sVEGFR-1 levels resulting in an imbalance of VEGF-A and
sVEGFR-1 levels in ocular tissues. Moreover, the sVEGFR-1 protein made was degraded
by the metalloproteinase (MMP) enzymes MMP-2, MMP-7 and MMP-9 produced by
infiltrating inflammatory cells that were principally neutrophils. Inhibition of neutrophils,
or inhibition of sVEGFR-1 breakdown with the MMP inhibitor (MMPi) marimostat, or
the provision of exogenous recombinant sVEGFR-1 protein all resulted in reduced
angiogenesis. Our results make the novel observation that ocular neovascularization
resulting from HSV infection involves a change in the balance between VEGF-A and its
soluble inhibitory receptor. Future therapies aimed to increase the production and activity
of sVEGFR-1 protein could benefit the management of SK, an important cause of human
blindness.

Introduction
Normal ocular function requires that photons can passage through ocular tissues
anterior to the retina with minimal impedance. In consequence, tissues anterior to the
retina are transparent and numerous strategies are used by the normal eye to maintain
transparency. These include mechanisms to suppress inflammatory and immune reactions
and means to suppress ocular vascularization, both enemies of normal vision (1, 2).
Nevertheless, in some circumstances, damage to the eye can result in chronic
inflammatory reactions and/or pathological neovascularization and these events may
seriously impair vision. This is often the outcome of ocular infection with Herpes
Simplex virus 1 (HSV-1) (3,4). Invariably, HSV-1 infection is followed by lifelong viral
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persistence and this source of virus can give rise to subsequent infections in the cornea (5,
6). Repeated recurrences often result in significant vision impairing lesions that occur
mainly in the corneal stroma (5, 6). Such stromal keratitis (SK) lesions have a complex
pathogenesis but result mainly from T cell orchestrated immunopathological reactions to
viral or perhaps unmasked ocular antigens (5, 7). Characteristically, SK also includes
pathological neovascularization that can be extensive, especially in animal models of SK
(8).
The therapeutic management of SK usually targets the inflammatory reaction but
controlling pathological angiogenesis also represents a useful approach, as has been
demonstrated in experimental situations (9, 10). Although several molecules may be
involved in pathological neovascularization, the VEGF family of proteins, especially
VEGF-A signaling through the VEGFR-2 receptor, is likely to be the most consequential
(11, 12). In support of this, inhibiting VEGF-A, or interfering with its receptor function,
were shown to be effective therapeutic strategies in mice models of SK (8-10).
One unsolved issue with regard to VEGF-A and pathological angiogenesis in SK, is the
source of the VEGF-A that induces neovascularization. Initial studies indicated that
VEGF-A was synthesized de novo in epithelial cells as a consequence of the infection,
although it is not clear if the primary source of VEGF-A is virus infected cells
themselves or nearby cells exposed to products released from infected and dying cells
(13, 14). Another VEGF-A source, especially after the initial event of SK pathogenesis,
may be infiltrating inflammatory cells, especially neutrophils that are prominent cells in
SK lesions (8). More recently, it was realized that VEGF-A is continuously produced in
biologically functional amounts by corneal epithelial cells. However, this source of
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VEGF-A fails to mediate angiogenesis because it is bound to a soluble form of the VEGF
receptor 1 (sVEGFR-1-1) (15). This so-called VEGF-A trap may be the primary reason
the undamaged cornea is not vascularized (15). Curiously, angiogenesis can be elicited in
the normal eye if the bond between VEGF-A and sVEGFR-1-1 is disrupted in some way
(15). Of interest, some species fail to express sVEGFR-1-1 and in one genetic disease of
humans, synthesis of the sVEGFR-1-1 molecule is defective (16). Both situations result
in corneal vascularization.
In light of the existence of the VEGF-A trap in normal eyes, pathological
angiogenesis, as for example can occur after HSV-1 infection, could also be influenced
by the balance between VEGF-A and the sVEGFR-1-1 molecules. We analyze this
possibility in the present communication. Our results confirm the previous report that
VEFG-A is present and bound to sVEGFR-1-1 in normal ocular tissue (15). We further
show that one consequence of HSV-1 infection is the occurrence of an imbalance in the
levels of VEGF-A and sVEGFR-1-1 mRNA and proteins. Our results could mean that
therapies designed to increase the presence, or retard the breakdown, of sVEGFR-1 may
be useful approaches to help manage the severity of SK, an important cause of blindness.

MATERIALS AND METHODS
Mice, Virus and cell lines. Female 6 to 8 week old C57BL/6 mice were purchased from
Harlan Sprague Dawley, Indianapolis, IN. Animals were housed in the animal facilities
approved by the Association for Assessment and Accreditation of Laboratory Animal
Care (AAALAC) at The University of Tennessee and all experimental procedures were in
complete agreement with the Association for research in Vision and Ophthalmology
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resolution on the use of animals in research. HSV-1 RE Tumpey and HSV-KOS viruses
were grown in Vero Cell monolayers (ATCC no. CCL81, American Type Culture
Collection). The virus was concentrated, titrated, and stored in aliquots at -800 C until
use. MK/T-1 cell line (Immortalised keratocytes from C57/BL6 mouse corneal stroma)
was kindly gifted by Dr. Reza Dana, Schepens Eye Research Institute and Department of
Ophthalmology, Harvard Medical School, Boston MA.
Corneal HSV-1 Infection and Clinical Scoring. Corneal infections of C57BL/6 mice
were conducted under deep anaesthesia induced by i.p. injection of avertin as previously
described (8). Mice were scarified on their corneas with 27-gauge needle, and a 3-µl drop
containing 1×104 PFU of virus was applied to the eye. The eyes were examined on
different days pi for the development and progression of clinical lesion by slit-lamp
biomicroscope (Kowa Company, Nagoya, Japan). The progression of SK lesion severity
and angiogenesis of individually scored mice was recorded. The scoring system was as
follows: 0, normal cornea; +1, mild corneal haze; +2, moderate corneal opacity or
scarring; +3, severe corneal opacity but iris visible; +4, opaque cornea and corneal ulcer;
+5, corneal rupture and necrotizing keratitis. The severity of angiogenesis was recorded
as described previously (17). According to this system, a grade of 4 for a given quadrant
of the circle represents a centripetal growth of 1.5 cm towards the corneal center. The
score of the four quadrants of the eye were then summed to derive the neo vessel index
(range 0-16) for each eye at a given time point.
Sub-conjunctival Injection. Subconjunctival injections of different drugs were
performed as described previously (18). Briefly, subconjunctival injections were done
using a 2-cm, 32-gauge needle and syringe (Hamilton, Reno, NV) to penetrate the
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perivascular region of conjunctiva, and the required dose of sVEGFR-1 or MMPi was
delivered into subconjunctival space. Control mice received isotype fusion protein or
solvent used for MMPi.
Treatment of mice with rsVEGFR-1‐1 and MMP inhibitor. 6- to 8-wk-old C57/BL6
mice were ocularly infected under deep anesthesia with 1×104 PFU of HSV-1 RE
Tumpey and divided randomly into groups. One group of mice was administered with 5
µg of rsVEGFR-1-1 (R & D Systems, Minneapolis, MN) in 7 µl PBS subconjunctivally
on 36 hours p.i. and then every alternate day from day 5 until day 13 postinfection. In
some experiments, rsVEGFR-1-1 was injected subconjunctivally every alternate day
starting from day 7 until day 13 postinfection. Animals in the control group were given
recombinant human IgG1 Fc protein (R & D Systems) following either of the regimens
for respective experiment. The MMPi, marimastat (200 µg /mouse) (Tocris Cookson Inc,
Ellisville, MO) was administered subconjunctivally either starting from day 2 or day 5 pi
followed by every alternate day until day 13pi. Mice in the control group were given the
mock injections. Mice were observed for the development and progression of
angiogenesis and SK lesions severity from day 7 until day 15 pi. In some experiments
MMPi treatment was started from day 2 and continued every alternate day until day 6 pi.
Mice were sacrificed on day 7 pi and corneas were collected for further analysis. All the
experiments were repeated at least two times.
Neutrophil Depletion with mAb. 6 to 8 week old C57/BL6 mice were ocularly infected
under deep anesthesia with 1×104 PFU of HSV-1 RE Tumpey and divided randomly into
groups. One group of animals was administered with 100 µg of anti-Gr-1 mAb (RB68C5; BioXcell, West Lebanon, NH) intraperitoneally on day 7 and 9 pi. Experiments
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were terminated on day 11 pi and corneal samples were collected for further analysis. To
study the effect of neutrophil depletion on HSV-1 mediated corneal angiogenesis,
antibody treatment was given every alternate day starting from day 7 until day 13 pi.
Mice were observed for the development and progression of angiogenesis and SK lesions
until day 15 pi. Animals in control group were given isotype control (IgG2b) Ab (LTF-2;
BioXcell) following the same regimen. All experiments were repeated at least two times.
Immunofluorescence staining. For immunofluorescence staining, the eyes from naïve
uninfected mice were enucleated, and snap frozen in OCT compound. Six-micron thick
sections were cut, air dried, and fixed in acetone-methanol (1:1) at room -20 0C for 10
min. Sections were blocked with 10% goat serum containing 0.05% Tween20 and 1:200
dilution of Fc block (Clone 2.42G2; BD Biosciences Pharmingen, San Diego, CA). Rat
anti-sVEGFR-1-1 (141515; R & D Systems) was diluted in 1% BSA containing 0.1%
Triton-X and incubated at room temp for 1 hr. After incubations sections were washed
several times with PBST and then stained with rabbit anti rat Alexa-488 for 45 min. The
corneal sections were repeatedly washed with PBST and mounted with ProLong gold
antifade mounting media containing DAPI as a nuclear stain (Molecular Probes,
Invitrogen) and visualized under a Immunofluorescence microscope. For Whole mount
corneal staining, corneas from rsVEGFR-1-1 and Isotype treated mice were dissected
under stereomicroscope. Corneal whole mounts were rinsed in PB for 30 min and
flattened on a glass slide under stereomicroscope. Corneal flat mounts were dried and
fixed in 100% acetone for 10 min at - 200C. Nonspecific binding was blocked with 5%
BSA containing 1:200 dilution of Fc block for 2 hr at 370C. CD31-PE (MEC13.3; BD
Biosciences-Pharmingen) antibody was used t a concentration of 1:250 in 1% BSA for
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overnight followed by subsequent washes in PBS. Corneas were mounted with ProLong
Gold antifade and visualized with fluorescence microscope.
Purification of Neutrophils. Ly6G+ neutrophils were purified from the pooled liberase
(Roche Diagnostics, Indianapolis, IN) digested corneal single cell suspension obtained
from HSV infected mice using anti-Ly6G+ microbeads (Miltenyi Biotec, Auburn, CA).
The purity was achieved at the extent of 90%. Purified neutrophils were further analyzed
by reverse transcription-PCR and WB for the expression of different MMPs.
Flow Cytometry. Corneas were excised, pooled group wise, and digested with 60 U/ml
Liberase for 35 minutes at 370C in a humified atmosphere of 5% CO2. After incubation,
the corneas were disrupted by grinding with a syringe plunger on a cell strainer and a
single-cell suspension was made in complete RPMI 1640 medium. The single cell
suspensions obtained from corneas were stained for different cell surface molecules for
FACS. All steps performed at 40C. Briefly, cell suspension was first blocked with an
unconjugated anti-CD32/CD16 mAb for 30 min in FACS buffer. After washing with
FACS buffer, samples were incubated with CD45-allophycocyanin (30-F11), CD11bPerCP (M1/79), Ly6G-PE (1A8), CD4-allophycocyanin (RM4.5) (All from BD
Biosciences-Pharmingen) for 30 min on ice. Finally, the cells were washed three times
and re-suspended in 1% para-formaldehyde. The stained samples were acquired with a
FACS Calibur (BD Biosciences) and the data were analyzed using the FlowJo software.
Quantitative PCR (QPCR). Corneal cells were lysed and total mRNA was extracted
using TRIzol LS reagent (Invitrogen). Total cDNA was made with 1 µg of RNA using
oligo(dT) primer. Quantitative PCR was performed using SYBR Green PCR Master Mix
(Applied Biosystem, Foster City, CA) with iQ5 real-time PCR detection ssystme (Bio
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Rad, Hercules, CA). The expression levels of different molecules were normalized to βactin using ΔCt calculation. Relative expression between control and experimental groups
were calculated using the 2-ΔΔCt formula. The PCR primers used are included as table 1 in
Supplemental information.
Reverse Transcription Polymerase chain reaction (RT‐PCR). RT-PCR was
performed to detect the presence of mRNA transcripts of various molecules (VEGF-A,
sVEGFR-11, beta actin and different MMPs) according to manufacturers protocol
(Promega, Madison, WI). Briefly, cDNA was prepared from total mRNA extracted from
different samples. cDNAs were amplified by PCR and were resolved on 1% agarose gel
The PCR primers used are included as table 1 in Supplemental information. The PCR
primers used are shown in table 2 in Supplemental information.
Western blot analysis. The supernatants from lysed corneal cells were quantified using
BCA protein Assay kit (Thermo scientific, Waltham, MA) using BSA as a standard and
samples with equal protein concentrations were denatured by boiling in Laemmli buffer.
Polypeptides were resolved by SDS-PAGE and transferred onto a PVDF membrane. The
membrane was blocked with 5% BSA in Tris-buffered saline with Tween20 (20 mM Tris
[pH 7.4], 137 mM NaCl, and 0.1% Tween20) overnight at 40C and probed with specific
primary and secondary antibodies. Proteins were detected using chemiluminiscent HRP
substrate (Millipore, Billerica, MA). The membrane was kept in stripping buffer for 10
min and re-probed using anti-β-actin antibody. The antibodies used were rat antisVEGFR-1-1 (141515; R&D Systems), mouse anti-VEGF-A (EE02; Santa Cruz
Biotechnology, Santa Cruz, CA), mouse anti MMP-2 (8B4; Santa Cruz Biotechnology,
Santa Cruz, CA), goat anti mouse MMP-8 (M-20; Santa Cruz Biotechnology, Santa Cruz,
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CA), goat anti mouse MMP-9 (C-20; Santa Cruz Biotechnology, Santa Cruz, CA), goat
anti mouse MMP-12 (M-19; Santa Cruz Biotechnology, Santa Cruz, CA), mouse anti-βactin (AC74; Sigma-Aldrich, St Louis MO), goat anti rat IgG-HRP (R & D Systems),
goat anti-mouse IgG-HRP (Santa Cruz Biotechnology) and donkey anti goat IgG-HRP
(Santa Cruz Biotechnology).
Coimmunoprecipitation.

Coimmunoprecipitation

was

performed

using

Pierce

Coimmunoprecipitation kit according to manufacturer’s protocol (Thermo Scientific).
Briefly, 50 µg of anti sVEGFR-1-1 antibody was immobilized to antibody coupling resin
by incubating the antibody to resin containing column for 2 hrs at room temperature.
Care was taken to keep resin slurry in suspension during incubation. The 200 µl
supernatant from lysed corneal cells (800 µg of total protein) was incubated for 2 hrs at
4oC with the above mentioned resin immobilized antibody. Finally, 50 µl of the elution
buffer was added and immunoprecipitate was eluted out and analyzed by WB.
ELISA. The pooled corneal samples were homogenized using a tissue homogenizer and
supernatant was used for analysis. The concentrations of VEGF-A and sVEGFR-1-1
were measured using Quantikine sandwich ELISA kits (R&D Systems) according to
manufacturers protocol.
Quantification of total number of molecules for sVEGFR-1 and VEGF-A. The total
number of sVEGFR-1 and VEGF-A molecules from naïve as well as different day pi
samples were calculated using following formula.
Total Number of Molecules = Quantity of Protein × Molecular Weight × Avogadro’s No.
In vitro assay for VEGF‐A and sVEGFR-1‐1 production. A mouse stromal fibroblast
cell line (MK/T-1) was used to study differential effect of HSV-1 on production of
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VEGF-A and sVEGFR-1-1. The cells were cultured and plated onto 6-well tissue culture
plates in 10% DMEM. The cells around >90% confluents were infected with HSV-KOS
at 3 multiplicity of infection (MOI) (adsorbption for 1 h). Uninfected cells were used as
control. Cells were harvested at different time points and total mRNA was extracted and
used to quantify the mRNA levels of the VEGF-A and sVEGFR-1-1.
Degradation assays. Degradation assays were performed as previously described (19).
Briefly, 100 ng of rsVEGFR-1-1 (R&D Systems) was incubated with active mouse
MMP-2, MMP-7, MMP-8, MMP-9 and MMP-12 (R&D Systems), at 1:1
substrate/enzyme molar ratio at 37°C for 24 hours. Pro-MMPs were activated by paminophenylmercuric acetate (Sigma-Aldrich) before use according to manufacturer’s
protocol. To study the degradation of mouse native sVEGFR-1-1 from cornea, the
supernatant from lysed corneal cells was collected and incubated with different activated
MMPs [1:1 substrate enzyme molar ratios] at 37°C for 24 hours. MMP activity was
inhibited using 20 mM ethylenediaminetetraacetic acid (EDTA). The samples were then
analyzed by WB.
Statistics. Student’s t test was performed to determine statistical significance and data are
expressed as mean ± SEM.

Results
Presence of VEGF-A in ocular tissues of normal mice
Recently, it was demonstrated that VEGF-A is present in normal corneal tissues,
but it fails to induce angiogenesis because it is bound to sVEGFR-1-1 (15). Both VEGF	
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A and sVEGFR-1-1 are produced continuously by normal ocular tissues. As a prelude to
measuring the influence of HSV-1 ocular infection on the balance between VEGF-A and
sVEGFR-1-1, we repeated some of the normal mice experiments previously described
(15). We were able to confirm many of their observations. Accordingly, as shown in
Figure-1, corneal extracts from naïve mice analyzed by WB under reducing conditions
revealed a band of 62kDa for sVEGFR-1-1 and two bands for VEGF-A at molecular
sizes of 22 and 14 kDa (Figure 3.1A). These bands correspond to two isoforms of VEGFA. However, under non-reducing conditions, blots revealed only a single band that was
far larger than those observed in reducing gels and had an apparent size of between 100150 kDa (Figure 3.1B). This would be consistent with VEGF-A being bound to another
molecule, presumably sVEGFR-1-1. Support for this was obtained performing coimmunoprecipitation that revealed the interaction of VEGF-A and sVEGFR-1-1 (Figure
3.1C).
The fact that normal ocular tissue expressed mRNA for both the VEGF-A and the
sVEGFR-1-1 proteins was also demonstrated by RTPCR (Figure 3.1D). The sVEGFR-11 molecule was also readily detectable in epithelial and stromal layers of corneal sections
by immunohistochemistry (Figure 3.1E). Our findings are consistent with and confirm
those reported by the Ambati group and demonstrate that VEGF-A is present in cornea
and is mostly bound to sVEGFR-1-1 forming a so called VEGF-A trap (15, 20-21).

Changes in VEGF-A and sVEGFR-1-1 as a consequence of HSV-1 infection
The principal objective of our study was to evaluate if the VEGF-A trap affected
the outcome of pathological angiogenesis caused by ocular infection with HSV-1. To do
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this, mice were ocularly infected with virus and the expression levels of both VEGF-A
and sVEGFR-1-1 mRNA and proteins were measured and compared with controls at
various times pi. We focused on initial time points after infection when replicating virus
is readily detectable in the cornea (up to 5 day pi) as well as at the stage of clinical SK
(day 8 pi) when replicating virus is no longer demonstrable and the stroma is heavily
infiltrated by inflammatory cells, particularly neutrophils (4, 22). At each time point, 6
corneas were collected and pooled for analysis from infected and control animals by
QPCR. The data expressed in Figure 3.2A records average gene expression values
compared with controls for 2 separate experiments. As is evident, increased VEGF-A
expression (6.7 fold) was detectable by 24 hours pi and levels peaked in the early phase
(average 11.5 fold) in samples tested on days 2 pi. By day 5, VEGF-A mRNA expression
levels were at control levels. However, VEGF-A mRNA levels increased in later samples
with the highest levels detectable (average 97 fold) in day 11 samples. At day 11,
replicating virus and viral mRNA were no longer present in corneal extracts (data not
shown) and the VEGF-A that was detected was presumed to be produced mainly by
infiltrating inflammatory cells such as neutrophils (described subsequently).
The general pattern observed measuring VEGF-A gene expression was evident
with protein levels measured by ELISA and WB. As shown in Figure 3.2B and 3.2C,
after an initial peak of VEGF-A protein on days 2 to 3 pi, a second higher peak was
observed during the clinical phase. The non-reducing WB of corneal extracts from naïve
mice revealed single high molecular weight band for VEGF-A (presumably all bound to
sVEGFR-1). However, corneal extracts from day 3 pi showed another low molecular
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weight band for VEGF-A suggesting the presence of non sVEGFR-1 associated free
VEGF-A after HSV-1 infection (Figure 3.2D).
Quantification of sVEGFR-1-1 gene expression revealed a different response
pattern than was noted with VEGF-A (Figure 3.2E). The expression levels were
decreased following HSV-1 infection with maximal decreases observed in samples taken
at 5 days pi (average 8 fold compared to control). The initial decreased expression of
sVEGFR-1-1 could reflect the well known ability of HSV to suppress almost all host
gene expression in cells in which it replicates (23, 24). However, VEGF-A gene
expression, at least early after infection, may be an exception as are some cytokines (13,
25, 26). To determine if HSV infection could differentially influence the expression of
VEGF-A and sVEGFR-1, we studied the outcome of in vitro infection of an eye derived
cell line (MK/T-1) that spontaneously expressed both VEGF-A and sVEGFR-1
(Supplemental Figure 3.1A). This cell line was derived from corneal stromal fibroblasts.
The results demonstrate that early after HSV-1 infection whereas VEGF-A levels were
increased, levels of sVEGFR-1 mRNA were markedly suppressed (Supplemental Figure
3.1B). Although fibroblasts are not the major cell type infected by HSV in vivo, our
results imply that a similar outcome could occur in corneal epithelial cells, the primary
target cells for HSV infection.
Experiments were also done to quantify protein levels at various time points by
ELISA. In corneal extracts of uninfected animals, sVEGFR-1-1 protein was readily
detectable, and these levels were far higher than VEGF-A in the same samples (Figure
3.2F). Changes in sVEGFR-1-1 protein levels detectable by ELISA did occur at different
time points after infection, and significant reduction in the levels of sVEGFR-1 were
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observed on day 1 and from day 5 to 11 pi. Additionally, when the ratio of the number of
sVEGFR-1 molecules to VEGF-A molecules from naïve mice was compared with
infected animals at various time points pi, there was a decreased ratio of sVEGFR-1 to
VEGF-A at all time points pi. Differences were significant on day 1 as well as from day 7
to 14 pi (Figure 3.2G). Furthermore, an interesting situation was revealed by WB analysis
under reducing conditions of samples taken at different time point pi (Figure 3.2H). Here
it was evident in corneal extracts from uninfected animals that sVEGFR-1-1 protein was
represented almost entirely as a single band at approximately 60 kDa size. However, by
day 3 pi, there was notable fragmentation of the sVEGFR-1-1 and this situation was also
evident in samples collected at other time points after infection. The degradation of
sVEGFR-1 could explain why we observed minimal sVEGFR-1 protein at day 11-time
point even though sVEGFR-1 mRNA levels peaked at this time. These observations led
us to conclude that HSV infection of the cornea diminished the expression of sVEGFR-11 and that the intact protein was degraded, at least partially, at different phases of virus
infection. Both effects would serve to diminish the inhibitory activity of sVEGFR-1-1 on
VEGF-A induced angiogenesis.
An additional series of experiments supported the notion that the activity of
sVEGFR-1-1 has a constraining effect on the angiogenic activity of VEGF-A. We
anticipated that the provision of an additional exogenous source of sVEGFR-1-1 protein
to HSV-1 infected mice might act to diminish the extent of angiogenesis that occurs
subsequent to infection. To evaluate this possibility, we obtained recombinant mouse
sVEGFR-1-1 (rsVEGFR-1-1) fusion protein that had previously been used by others to
counteract VEGF-A activity in a VEGF-A induced micro-pocket assay for angiogenesis
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(15). In our pathological system, we chose to administer a higher dose rsVEGFR-1-1, or
an isotype fusion protein (Isotype). To evaluate the possible VEGF-A inhibitory effects
in vivo, animals were given either rsVEGFR-1-1 or Isotype subconjunctivally to HSV-1
infected animals, either starting at day 1 (Figure 3.3A) or day 7 pi (Figure 3.3E). Animals
were followed until day 15 pi to measure the extent of angiogenesis. Results shown in
Figure 3.3A-C and Supplemental Figure 3.2A indicated that rsVEGFR-1-1 recipients had
significantly diminished angiogenic responses as well as SK lesion severity compared to
the isotype group. Corneal cell preparations collected at the end of the experiment
revealed diminished frequency and numbers of CD31+ (a marker for blood vessel
endothelial cells), neutrophils as well as CD4+ T cells (Figure 3.3D and Supplemental
Figure 3.2B). It is of particular interest to note that even when rsVEGFR-1-1
administration was delayed till day 7 pi (Figure 3.3E), a significant level of SK severity
and angiogenesis inhibition was still evident. These results further support the concept
that sVEGFR-1-1 may limit the angiogenic response to VEGF-A in pathological
angiogenesis.

Metalloproteinases could be responsible for sVEGFR-1-1 degradation
The observation that sVEGFR-1-1 protein may be degraded in HSV-1 infected
corneas raised the question of how the breakdown was accomplished. Likely enzyme
candidates include MMPs, some of which were shown to be present in damaged eyes in
other systems (1). Previous reports suggest that MMP-9 could induce neovascularization
in vivo and inhibition of MMP-9 reduces angiogenesis (27). Moreover, MMP-9 protein
is present in the cornea following HSV-1 infection as we have reported previously (28).
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Experiments were performed to measure the expression profile by QPCR of several
MMP mRNAs at various time points after HSV-1 infection. The results shown in Figure3.4A demonstrate that compared to uninfected controls, expression levels of several
MMPs were elevated following the infection. Peak levels that varied between
experiments differed between the MMPs tested, but always occurred between days 5 and
days 11 pi. Of the multiple MMP mRNAs examined, expression levels of MMP-9 were
the most elevated with its peak evident in day 7 pi samples (Average 249 fold). Another
MMP of interest was MMP-7 since this enzyme was shown recently to be uniquely
capable degrading human sVEGFR-1-1 (19). Levels of MMP-7 were at their peak on day
11 pi. Additional experiments were done in vitro with the activated form of selected
MMPs (MMP-2, MMP-7, MMP-8, MMP-9, and MMP-12) to measure their ability to
degrade rsVEGFR-1-1 in vitro as detected by WB. As is evident in Figure 3.4B, MMP-7
was most effective at degrading rsVEGFR-1-1 with MMP-9 also active, but less so. In
these assays, MMP-8 and MMP-12 were without activity and MMP-2 had a minimal
effect. In additional experiments, MMP-2, MMP-7 and MMP-9 were shown to degrade
sVEGFR-1-1 present in naïve corneal extracts (Figure 3.4C).
Experiments were also done to determine if inhibiting the function of MMP
enzymes in vivo affected sVEGFR-1-1 degradation, as well the outcome on the extent of
angiogenesis and SK severity. To accomplish MMP inhibition, marimastat (29-31) was
administered subconjunctivally at different times pi and the results compared to infected
mice given subconjunctival injections of mock. In an experiment in which animals
received marimastat on days 2,4 and 6 pi, corneal extracts examined by WB on day 7 pi
revealed a markedly reduced level of sVEGFR-1-1 degradation compared to controls
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(Figure-3.5A). In another experiment, two marimastat injections given on days 2 and 4
also revealed inhibited sVEGFR-1-1 degradation in samples examined on day 5 (Data not
shown).
When the outcome of angiogenesis and SK severity was compared in treated and control
mice, the marimastat recipients had significantly reduced levels of angiogenesis and SK
severity, at least at day 15 pi time point when experiments were terminated (Figure 3.5B).
Corneal cell preparations collected at the end of the experiment revealed diminished
frequency and numbers of CD31+ endothelial cells, neutrophils and CD4+ T cells (Figure
3.5C and Supplemental Figure 3.3A). Furthermore, in an experiment in which marimastat
treatment was begun on day 5 pi and given additional injections on days 7, 9 and 11 there
was also a significant reduction of angiogenesis and lesion scores at day 15 pi (Figure
3.5D). Corneal cell preparations collected at the end of the experiment revealed
diminished frequency and numbers of CD31+ endothelial cells, neutrophils as well as
CD4+ T cells (Figure 3.5E and Supplemental Figure 3.3B). Taken together our results
support the concept that metalloproteinases, particularly MMP-2, MMP-7 and MMP-9,
are upregulated following HSV-1 infection and these enzymes are responsible for
degrading the sVEGFR-1-1 protein that, in turn, constrains the angiogenic activity of
VEGF-A.

Neutrophils play multiple roles in ocular angiogenesis
A prominent cell type in the inflammatory response to ocular HSV-1 infection is
the neutrophil (8, 13, 22). To investigate the role played by neutrophils in HSV-1
mediated corneal angiogenesis, kinetic studies were carried out for neutrophil infiltration
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in the cornea following HSV infection. As shown in Figure 3.6A, neutrophils constitute
about 30-80% of total infiltrated leukocytes at all tested time points and infiltrate the
cornea in a biphasic manner. An initial wave of infiltration peaked around day 2 pi
followed by decline and second wave starting from day 8 till which peaked around day
15 pi (Figure 3.6B). Since, neutrophils studied in other systems are known to be a source
of different MMPs as well as VEGF-A (28, 32-34); we anticipated that neutrophils could
be a source of MMP enzymes that act to increase angiogenesis by breaking down and
releasing bioactive VEGF-A from its bond to sVEGFR-1-1. In support of this, we
purified neutrophils from the day 2 infected corneas and WB analysis was carried out to
check the presence of protein for MMP-2, MMP-8, MMP-9 and MMP-12. Figure 3.6C
shows the presence of MMP-2, MMP-8, MMP-9 and MMP-12. Additionally, depleting
neutrophils from day 7 pi (Figure 3.6D) in infected mice led to significantly diminished
VEGF-A protein levels and restored levels of sVEGFR-1-1 protein in day 11 samples
(Figure 3.6E). QPCR analysis also revealed the decreased expression of VEGF-A and
MMP-9 in the depleted mice as compared to isotype antibody treated mice (Figure 3.6F).
To further implicate neutrophils as a source of VEGF-A during the clinical phase of SK,
neutrophils were purified from pooled corneas at day 11 pi and RTPCR and WB carried
out to check for the presence of VEGF-A mRNA message as well as protein. Both
VEGF-A mRNA (Figure 3.6G) and protein (Figure 3.6H) could be demonstrated
supporting a role for neutrophils in contributing to angiogenesis during the clinical phase
of SK when replicating virus is no longer present in the cornea.
To show the influence of neutrophils during HSV-1 induced pathological
angiogenesis, experiments were done to compare the extent of angiogenesis and
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differences in expression levels of VEGF-A and sVEGFR-1-1 in mice depleted of
neutrophils compared to controls. Depletion (with anti-Gr1 MAb) was commenced on
day 7 pi. As shown in Figure 3.6I, whereas the extent of angiogenesis and SK lesion
severity continued to increase in magnitude in isotype antibody treated animals, by day
15 pi, when the experiment was terminated, the average angiogenic response and SK
severity were significantly decreased in animals treated with neutrophil depleting
antibody. Although, cell types in inflammatory reaction other than neutrophils can
express Gr1, neutrophils are the predominant Gr1+ population in lesion during clinical
phase of SK. We interpret Gr-1 depletion experiment where the VEGF-A levels were
decreased to mean that neutrophils represent a major source of the VEGF-A that is
involved in HSV-1 induced angiogenesis even though a minority of other cell types in
inflammatory reaction can also be Gr1+. Taken together these results demonstrate that
neutrophils contribute to the severity of the pathological angiogenic response caused by
HSV-1 infection. This occurs because neutrophils, can act as one of the sources of
VEGF-A as well as the MMP enzymes that degrade sVEGFR-1-1, the molecule that
binds to VEGF-A and inhibit its angiogenic activity.

Discussion
In this report, we investigate mechanisms by which HSV-1 infection of the eye
results in neovascularization, an essential step in the pathogenesis of SK, an ocular lesion
that impairs and can ablate vision (35). We confirm a previous report (15) that VEGF-A,
a principal angiogenic factor, is produced by the normal eye, but is constrained from
causing angiogenesis by being bound to a soluble form of one of its cellular receptors.
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Our results make the novel observation that one consequence of HSV-1 infection is to
cause an imbalance in the production of VEGF-A and sVEGFR-1-1 that impedes its
activity. Whereas, the infection up-regulates VEGF-A production, the expression of
sVEGFR-1-1 is inhibited. Moreover, the sVEGFR-1-1 protein that is made is degraded
by the metalloproteinase enzymes MMP-2, -7 and -9 which permits the VEGF-A,
initially derived from infected epithelial cells, and later on inflammatory cells, to exert
more effective angiogenic activity. Procedures that decrease the breakdown of sVEGFR1-1, such as the administration of the MMPi, marimastat, or the provision of exogenous
rsVEGFR-1-1 protein resulted in lessened angiogenesis. Our results support the notion
that the binding of sVEGFR-1-1 to VEGF-A, a so called VEGF-A trap, acts to limit the
extent of pathological angiogenesis such as that caused by ocular infection by HSV-1. It
is also conceivable that future therapies to control SK could benefit by procedures that
influence the production and activity of the sVEGFR-1-1. Our overall results are
summarized in Figure-3.7, showing how HSV-1 infection leads to corneal angiogenesis.
The pathogenesis of SK involves multiple events that include neovascularization
of the normally transparent tissue anterior to the retina. Thus any new blood vessel
development in the anterior tissues damages vision by defracting light and, since new
vessels are leaky (4, 11), they readily permit escape of inflammatory cells that further
contribute to the loss of transparency. Accordingly, preventing, and ideally reversing,
neovascularization is an important objective to retain optimal vision. Numerous
mechanisms have been suggested to explain how HSV infection could cause
neovascularization (8, 28, 36), but perhaps the most important is the induction of VEGF
family members, especially VEGF-A which stimulates corneal angiogenesis by engaging
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the receptor VEGFR-2 (8, 10). Supporting this, prior studies have shown that
counteracting the VEGF-A made or inhibiting its receptor can significantly reduce HSV
induced angiogenesis (8, 10). Others, as well as ourselves, have already reported that
HSV infection of the corneal epithelium in the early stages of keratitis results in the
expression of VEGF-A protein either in infected or nearby cells (13, 14). What we had
not appreciated, until the observations of the Ambati group appeared (15), is that VEGFA is continually produced by uninfected normal eyes but fails to cause corneal
vascularization because the VEGF-A is bound to a soluble form of one of its receptors
(15). The important aspect of our study is our observations that the binding of sVEGFR1-1 to VEGF-A made during a pathological disease process may also act to modulate
VEGF-A activity and influence the magnitude of angiogenesis. A series of observations
led to this conclusion.
Firstly in the early stages after HSV infection much of the VEGF-A detected by
WB under native conditions was of a molecular size consistent to its being bound to
another protein that was shown to be sVEGFR-1-1. Of interest, soon after infection one
consequence of HSV-1 was to exert a differential effect on gene expression of VEGF-A
and sVEGFR-1-1 proteins. Accordingly, whereas infection caused an increased
expression of VEGF-A, the production of the sVEGFR-1-1 was inhibited. Additionally,
that infection of cells could enhance VEGF-A, but suppress sVEGFR-1-1, gene
expression could also be shown by in vitro studies. Thus the initial angiogenesis observed
after infection could be the consequence of enhanced VEGF-A activity arising both from
increased production as well as diminished inhibition. In support of the latter mechanism,
if an additional exogenous source of sVEGFR-1-1 was provided during the early stages
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of the disease process, the outcome was diminished angiogenesis. These observations
taken together support the idea that a VEGF-A trap operates to limit the extent of
pathological angiogenesis at least early after infection.
It is characteristic of HSV-1 ocular infection in the mouse model that the virus is
cleared within a few days, but the extent of angiogenesis continues to advance as does the
chronic inflammatory process in the corneal stroma that is indicative of SK (4, 8). Our
studies show that VEGF-A may also be responsible for the additional angiogenesis but
the principal cell source of the VEGF-A is no longer the epithelium (that is no longer
infected) but instead derives from invading inflammatory cells, particularly neutrophils.
We could show that depleting Gr1+ cells with specific mAb on day 7 pi diminished the
extent of the neovascular response compared to non-depleted controls indicating their
role in VEGF-A production. Depleted animals also had less VEGF-A protein in corneal
extracts when quantified by ELISA. However, we anticipated that at the later phases of
the disease process, the activity of VEGF-A was less likely to be impeded by its binding
to the sVEGFR-1-1 protein. Thus, in addition to being a source of VEGF-A the invading
inflammatory cells are well known to produce many different MMP enzymes (28, 37)
some of which could degrade proteins that bind to VEGF-A and limit its activity (34).
For example, in some cancer systems where VEGF-A is shown to be bound to a matrix
protein, MMP-9 may degrade the matrix protein so releasing VEGF-A to exert
angiogenic activity (38). Moreover, VEGF-A processed by different MMPs retains
biological activity (39). Also of relevance, MMP-7 was shown very recently to degrade
human sVEGFR-1-1 resulting in increased angiogenic activity in an in vitro tube
formation assay using human umbilical vein endothelial cells (19). In our present study,
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we could demonstrate that the inflammatory exudate cells could express several MMPs
and that at least two of them (MMP-7 and MMP-9) were highly effective in vitro at
degrading the mouse sVEGFR-1-1 protein, that had not previously been reported. We
could show the effect using a recombinant sVEGFR-1-1 protein as well as with
sVEGFR-1-1 preparations isolated from normal mouse corneas. However, of special
relevance to our viewpoint as the constraining role of sVEGFR-1-1 on VEGF-A activity,
we could clearly demonstrate that if we treated animals with marimastat, an inhibitor of
MMP enzyme activity, then the extent of the neovascular response was significantly
diminished compared to untreated animals. Furthermore, WB revealed that sVEGFR-1-1
protein concentrations were higher in marimastat treated corneal samples.
Taken together we contend that our studies have provided novel insight on
mechanistic aspects of SK pathogenesis and have revealed a previously unrecognized
event that could be targeted for therapeutic manipulation. Accordingly, we show that the
important event of ocular angiogenesis mediated by VEGF-A is markedly influenced by
the presence and activity of the sVEGFR-1-1 protein. When bound to sVEGFR-1-1, as
occurs with all of the VEGF-A made by the normal cornea, VEGF-A is unable to
mediate angiogenesis. In a pathological situation this VEGF-A trap is also occurring, but
it breaks down when levels of MMPs arrive that can degrade the sVEGFR-1-1 protein
(Fig 7). It would seem logical to develop therapies to manage SK that either increase the
concentration or retard the breakdown of the sVEGFR-1-1 protein. Further studies are
underway to investigate this issue.
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FIGURE 3.1. NORMAL CORNEA EXPRESSES VEGF-A BOUND TO SVEGFR-1.
WT mice were sacrificed and 4 to 6 corneas were collected and pooled for WB,
Co-immunoprecipitation, and mRNA analysis by RTPCR. Data are representative of two
independent experiments. (A) Reducing WB analysis for sVEGFR-1 and VEGF-A
reveals presence of sVEGFR-1 at 62 kDa and two isoforms of VEGF-A at 22 and 16 kDa
in normal cornea. (B) Non-reducing WB for VEGF-A shows the presence of a much
larger band between molecular size of 100 to 150 kDa consistent with its being the bound
form. (C) sVEGFR-1 was immunoprecipitated from normal corneal extracts, with anti
sVEGFR-1 mAb and the complex was analyzed for the co-immunoprecipitation of
VEGF-A by WB. Normal cornea shows the presence of VEGF-A bound to sVEGFR-1.
(D) Agarose gel analysis of VEGF-A (214bp) (lane 3) and sVEGFR-1 (358bp) (lane 5)
cDNA from normal uninfected cornea. Lane M-marker, lane 1- β-actin (92bp), lane 2, 4
and 6 are reverse transcriptase negative controls for β- actin, VEGF-A and sVEGFR-1.
(E) Representative immunofluorescence staining of corneal section for sVEGFR-1
(green, left panel), nuclei (blue, middle panel) reveals the presence of sVEGFR-1 mainly
in the corneal epithelial layer and to a lesser extent in the stroma (Merge). Nuclei were
stained (blue) with DAPI. Image is representative of two independent experiments.
Original magnification × 10.
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FIGURE 3.2 CORNEAL HSV-1 INFECTION CAUSES AN IMBALANCE BETWEEN VEGFA
AND SVEGFR-1.

WT mice corneas were scarified and infected with 104 PFU of HSV in PBS or
mock infected with only PBS (naïve control mice). Corneas were harvested from infected
mice at indicated time points PI and from naive control mice at 24 hr. (A) At each time
point 6 corneas were collected and pooled for mRNA extraction. The expression levels of
VEGF-A molecule were normalized to β-actin using ΔCt calculation. Relative expression
between control and infected groups were calculated using the 2–ΔΔCt formula. Kinetic
analysis for the expression of VEGF-A mRNA by quantitative PCR (QPCR) at different
days pi. The expression of VEGF-A shows a biphasic upregulation pattern, early on day 2
pi and then again on day 11 pi as compared to naïve cornea. Figure is a summary of two
independent experiments and each experiment represent group of 6 corneas. (B) At each
time point 6 corneas were harvested from infected or naïve mice and the levels of VEGFA were determined by ELISA. Quantification of VEGF-A protein levels in the normal
and infected corneas at different days pi reveals similar pattern as that of gene expression.
Figure is a summary of at least two independent experiments and each experiment
represent group of 6 corneas. P ≤ 0.009 (**), P = 0.0004 (***). (C) At each indicated
time points 3-4 corneas were harvested and total protein concentration were measured by
BCA protein assay. Samples with equal protein concentration were subjected to SDSPAGE followed by WB analysis. VEGF-A expression was analyzed by WB analysis
showed an increase in the VEGF-A protein levels at different days pi compared to naïve
control mice. (D) Three to four corneas were harvested from day 3 pi or naïve control
mice at 24 hr pi. Samples with equal protein concentration were subjected to native	
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PAGE followed by WB analysis. The left figure shows a band of molecular size between
100 to 150 kDa in naïve corneal sample. The right is from day 3 infected corneas. It
shows the large 100-150 kDa band as well as another at 50 kDa indicating the presence of
both bound and free VEGF-A. (E) Kinetic analysis for the expression of sVEGFR-1
mRNA by QPCR at different days pi. Relative change in the expression of sVEGFR-1
mRNA at different days pi as compared to the uninfected mice revealed a sharp decrease
in the sVEGFR-1 expression from day 3 pi which reached above normal around day 11 pi
and back to normal levels at day 14 pi. The figure is a summary of two independent
experiments and each experiment represent group of 6 corneas. (F) sVEGFR-1 protein
levels analyzed by ELISA from the normal and infected corneas at different days pi
shows an early decrease after HSV-1 infection which reaches to level found in normal
controls at day 14 pi. The figure is a summary of at least two independent experiments
and each experiment represent group of 6 corneas. P ≤ 0.05 (*), P = 0.0023 (**), P ≤
0.0001 (***). (G) Quantification of total number of sVEGFR-1 molecules per VEGF-A
molecule from naïve and infected corneas at different days pi using protein quantities
obtained by ELISA (B & F) shows the significant reduction of total number of sVEGFR1 molecules per VEGF-A molecule on day 1 and from day 7 to 14 pi. The total number of
molecules for sVEGFR-1 and VEGF-A were calculated by multiplying the total quantity
of the protein by its molecular weight and Avogadro’s number. The figure is a summary
of values obtained from figure B and F. P = 0.0216 (*), P ≤ 0.0032 (**), P ≤ 0.0002
(***). (H) Reducing WB analysis for sVEGFR-1 from uninfected and infected corneas at
different time pi shows degradation of sVEGFR-1 after HSV-1 infection. Degraded
products are shown by black arrowhead.
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FIGURE 3.3. RSVEGFR-1 ADMINISTRATION HINDERS ANGIOGENIC ACTIVITY OF VEGFA AND INHIBITS CORNEAL ANGIOGENESIS POST HSV-1 INFECTION.
WT mice were ocularly infected by corneal scarification with 104 PFU of HSV.
(A) rsVEGFR-1 or isotype Fc protein were administered subconjunctivally at 5 µg/eye as
shown. The extent of angiogenesis and SK lesion severity in the eyes of HSV infected
mice were quantified in a blinded manner using a scale as described in materials and
methods. The progression of angiogenesis and SK lesion severity were significantly
reduced in the group of mice treated with rsVEGFR-1 as compared to isotype treated
mice. Data are representative two independent experiments (n = 10-12 mice/group). P ≤
0.0007 (***). (B) Representative whole mount corneas stained for CD31 (lower panel) at
day 15 pi shows reduced angiogenic response in rsVEGFR-1 treated mouse. Bars,
100µm. (C) Representative eye photos shows reduced SK lesion severity as well as
angiogenesis from rsVEGFR-1 treated mouse compared to isotype treated mouse. (D)
rsVEGFR-1 or isotype Fc protein treated mice were sacrifice on day 15 pi and corneas
were collected for surface staining of eye infiltrating cells. Total cell numbers per cornea
for CD31+ cells, Neutrophils (CD11b+, Ly6G+ cells) gated on total CD45+ cells and CD4+
T cells showed the significant reduction in total numbers of the respective cell population
from rsVEGFR-1 treated mice as compared to the isotype treated mice. Data are a
representative of two independent experiments (n = 3-5/group). P = 0.012 (*), P ≤ 0.0015
(**). (E) Therapeutic administration of the rsVEGFR-1 was started from day 7 pi when
SK becomes visibly evident. Therapeutic administration of rsVEGFR-1 also showed
significant reduction in angiogenesis as well as lesion severity further confirming the
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inhibitory effect of sVEGFR-1 on the angiogenic activity of VEGF-A. Data are a
representative of two independent experiments (n = 8 mice/group). P ≤ 0.012 (*).
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FIGURE 3.4. METALLOPROTEINASES ARE UPREGULATED AFTER HSV-1 INFECTION AND
MMP-2, 7 AND 9 DEGRADES RSVEGFR-1 AND SVEGFR-1.
(A) WT mice corneas were scarified and infected with 104 PFU of HSV in PBS or
mock infected with only PBS (naïve control mice). Corneas were harvested from infected
mice at indicated time points PI and from naive control mice at 24 hr. At each time point
6 corneas were collected and pooled for mRNA extraction. The expression levels of
different MMP molecule were normalized to β-actin using ΔCt calculation. Relative
expression between control and infected groups were calculated using the 2–ΔΔCt formula.
Kinetic analysis for the relative fold change in the expression levels of MMP- 2, MMP-7,
MMP-8, MMP-9 and MMP-12 mRNAs at different days pi. The mRNA expression of all
the tested MMPs was upregulated in biphasic manner post HSV-1 infection with the first
peak expression at day 1 pi and maximum expression between day 7 and day 11 pi. (B)
Mouse rsVEGFR-1 was incubated with activated form of MMP-2, MMP-7, MMP-8,
MMP-9 and MMP-12 for 12 hrs at 370C and analyzed by WB. MMP-7 (lane 3) showed
maximum degradation of rsVEGFR-1 followed by MMP-9 (lane 5) and MMP-2 (lane 2).
Addition of the MMP inhibitor, EDTA, inhibited the degradation of rsVEGFR-1 by
MMP-7 (lane 7) and MMP-9 (lane 8). Figure is a representative of three independent
experiments. (C) Corneal lysates from 4-6 pooled corneas of uninfected WT mice were
incubated with activated form MMP-2, MMP-7, MMP-8, MMP-9 and MMP-12 either for
6 hr or 12 hr at 370C. The digested corneal lysates were analyzed by WB for sVEGFR-1.
MMP-7 showed degradation of corneal sVEGFR-1 even after 6 hrs of incubation (upper
panel, lane 2), with complete degradation after 12 hrs of incubation (lower panel, lane 2).
MMP-2 (lower panel, lane 1) and MMP-9 (Lower panel lane 4) also showed degradation
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of corneal sVEGFR-1 after 12 hrs of incubation. Addition of MMP inhibitor EDTA with
MMP-7 (lane 6) showed inhibition of sVEGFR-1 degradation. Figure is a representative
of three independent experiments.
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FIGURE 3.5. BLOCKING MMPS ACTIVITY IN VIVO RESCUES SVEGFR-1 DEGRADATION
AND DIMINISHES ANGIOGENESIS AND SK SEVERITY.

WT mice corneas were scarified and infected with 104 PFU of HSV or mock
infected with only PBS (naïve control mice). Marimastat, a broad-spectrum MMP
inhibitor (MMPi) was administered subconjunctivally at 200 ug/mouse as shown. Mice in
control group received HSV infection with mock treatment. (A) WB analysis of the
corneal lysates collected from naïve (N), control treated (C) and MMPi treated mice at
day 7 pi shows that MMPi rescues degradation of sVEGFR-1 post HSV-1 infection. The
figure is a representative of two independent experiments. (B) Preventive treatment of
MMPi in mice infected with HSV-1 was started from day 2 pi as shown. MMPi treatment
showed a significant reduction of angiogenesis as well as SK lesion severity at day 15 pi.
Data are representative of two independent experiments (n = 9-12 mice/group). P ≤ 0.04
(*), P = 0.0065 (**). (C) MMPi treated or control mice were sacrifice on day 15 pi and
corneas were collected for surface staining of eye infiltrating cells. Analysis for total cell
numbers per cornea for CD31+ cells, neutrophils (CD45+ CD11b+ Ly6G+ cells) and CD4+
T cells showed significant reduction in frequencies as well as total numbers of the
respective cell population in the MMPi treated mice. Data are a representative of two
independent experiments (n = 7/group). P = 0.0115 (*), P = 0.0078 (**), P = 0.0002
(***). (D) Therapeutic administration of the MMPi (started from day 5 pi), also showed
reduced angiogenesis as well as SK lesion severity at day 15 pi. Data are a summary of
two independent experiments (n = 6 mice/group). P ≤ 0.021 (*). (E) Analysis of total cell
numbers per cornea for CD31+ cells, neutrophils (CD45+CD11b+, Ly6G+ cells) and CD4+
T cells also showed the significant reduction in the total cell numbers per cornea after
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preventive MMPi treatment. Data are a representative of two independent experiments (n
= 5-6/group). P ≤ 0.0094 (**).
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FIGURE 3.6. NEUTROPHIL, THE PRINCIPAL CELL IN CORNEA AFTER HSV-1 INFECTION IS
SOURCE OF MMPS AND

VEGF-A.

WT mice corneas were scarified and infected with 104 PFU of HSV or mock
infected with only PBS (naïve control mice). At each indicated day pi two mice were
sacrificed, corneas were harvested and single cell suspensions were analyzed for surface
staining by flow cytometry. (A) Representative FACS plot from each time point shows
the percentage of neutrophils (CD11b+Ly6G+) gated on total CD45+ cells. (B) Total
number of neutrophils per cornea at each indicated time point post HSV-1 infection. Data
are expressed as mean ± SEM. Figure is a summary of two independent experiments and
each experiment represent group of 2 corneas. (C) Ly6G+ neutrophils were purified from
day 2 pi corneas using anti-Ly6G beads. Cell suspension from 6-8 pooled corneas was
used for neutrophil purification. Western blot analysis for MMP-2, MMP-8, MMP-9 and
MMP-12 from purified neutrophils. Data is from single experiment and represent
neutrophils from group 6-8 corneas. (D) Neutrophil depletion was carried out from day 7
pi, using anti-Gr-1 mAb (100 µg/mice, intra-peritoneally) as shown. Mice in the control
group received isotype control antibody. Representative FACS plot shows complete
depletion of neutrophils from spleen (upper panel) and cornea (lower panel) analyzed at
day 11 pi. (E) Corneal lysates from normal (N), isotype control antibody treated (IC) and
neutrophil depleted (Gr-1) from day 11 pi mice, were analyzed by WB for VEGF-A
(upper panel), sVEGFR-1 (middle panel). Figure is a representative of two experiments
and each experiment represent at least 3 corneas. (F) Relative fold change in the
expression of VEGF-A and MMP-9 mRNA in neutrophil depleted and isotype antibody
treated mice at day 11 pi as compared to naïve mock infected mice. Figure is a
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representative of two experiments and each experiment represent at least 4 corneas.
Ly6G+ neutrophils were sorted from day 11 pi corneas. Cell suspension from 6-8 pooled
corneas was used for neutrophil purification. Purified neutrophils were analyzed by either
WB or RTPCR for the expression of VEGF-A. (G) Reducing WB analysis for VEGF-A
from two different samples S1- Sample 1 and S2-Sample 2 shows the presence of VEGFA protein from purified neutrophil samples. Data represent two different experiments and
each sample represent neutrophils from 6-8 corneas. (H) Agarose gel analysis for β-actin
(92bp) (lane 2) and VEGF-A (214bp) (lane 4) of cDNA from purified neutrophils. Lane 1
and 3 are reverse trancriptase negative control for β-actin and VEGF-A respectively. (I)
Neutrophil depletion started from day 7 pi and continued until day 13 pi resulted in
reduced angiogenesis as well as SK lesion severity. Data are representative of a two
independent experiments (n = 8-10 mice/group). P = 0.0131 (*), P = 0.0068 (**).
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FIGURE 3.7. SCHEME ILLUSTRATING THE MECHANISM FOR HSV-1 MEDIATED CORNEAL
ANGIOGENESIS.

Normal uninfected cornea constitutively secretes large amount of sVEGFR-1 and
small amounts of VEGF-A. sVEGFR-1 constrains the physiological effect of VEGF-A by
binding it with very high affinity (Left panel). Early after corneal HSV-1 infection, there
is sudden increase in the levels of VEGF-A primarily being produced by infected or
nearby uninfected corneal epithelial cells. However, levels of sVEGFR-1 go down
mainly due to decreased production of sVEGFR-1 by corneal epithelial cells and also due
to degradation by MMP-2, MMP7 and MMP9. This in turns leads to more
physiologically active VEGF-A, which is now free from inhibitory effect of sVEGFR-1.
This active form of VEGF-A drives the initial angiogenic sprouting early after HSV
infection (middle panel). During chronic phase of HSK, when HSV-1 is no longer
detected in the cornea, inflammatory cells particularly neutrophils act as a source of
VEGF-A and different MMPs. This second wave of VEGF-A and MMPs further
maintains the angiogenic response by continuous supply of active form of VEGF-A and
MMPs, which degrades sVEGFR-1. The development of new leaky blood vessels leads
to the release of more plasma and inflammatory cells in the cornea thus setting the stage
for chronic SK and blindness (Left Panel).
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SUPPLEMENTAL FIGURE 3.1: HSV-1 INFECTION OF MK/T-1 CELLS DIFFERENTIALLY
REGULATES THE EXPRESSION OF SVEGFR-1 AND VEGF-A.

(A) Uninfected MK/T-1 cells express both VEGF-A (214bp) (lane 3) and
sVEGFR-1 (358bp) (lane 5) as shown by agarose gel analysis for cDNA. Lane Mmarker, lane 1- β-actin (92bp), lane 2, 4 and 6 are reverse transcriptase negative controls
for β- actin, VEGF-A and sVEGFR-1. Figure is representative of two independent
experiments. (B) MK/T-1 cells were infected with 3 MOI of HSV-KOS. At each time
point cells were harvested for mRNA extraction. The expression levels of VEGF-A and
sVEGFR-1 molecule were normalized to β-actin using ΔCt calculation. Quantification of
VEGF-A and sVEGFR-1 mRNA at different time point shows differential gene
expression post HSV infection as compared to uninfected cells. Data are expressed as
mean ± SEM. Figure is a summary of two independent experiments.
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SUPPLEMENTAL FIGURE 3.2.

RSVEGFR-1 TREATMENT POST HSV INFECTION

DIMINISHES ANGIOGENESIS AND SK LESION SEVERITY.

WT mice were ocularly infected by corneal scarification with 104 PFU of HSV.
(A) rsVEGFR-1 or isotype Fc protein were administered subconjunctivally at 5 µg/eye as
shown. The extent of angiogenesis and SK lesion severity in the eyes of HSV infected
mice were quantified in a blinded manner using a scale as described in materials and
methods. Cumulative scores for angiogenesis and SK lesion severity at day 15 pi. (n =
17-22 mice/group). Data are a summary of two independent experiments. P = 0.0001
(***). (B) Mice were sacrifice on day 15 pi and corneas were collected for surface
staining of eye infiltrating cells. Representative FACS plot for CD31+ cells, Neutrophils
(CD11b+, Ly6G+ cells) gated on total CD45+ cells and CD4+ T cells showed reduced
frequencies of respective cell population in the rsVEGFR-1 treated mice as compared to
the isotype treated mice.
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SUPPLEMENTAL FIGURE 3.3. MMPI TREATMENT REDUCES THE FREQUENCIES CD31+
+

ENDOTHELIAL CELLS, NEUTROPHILS AND CD4

T CELLS.

WT mice corneas were scarified and infected with 104 PFU of HSV or mock
infected with only PBS (naïve control mice). Marimastat, a broad-spectrum MMP
inhibitor (MMPi) was administered subconjunctivally at 200 ug/mouse preventively (A)
or therapeutically (B) as shown. Mice in control group received HSV infection with mock
treatment. Representative FACS plot and total cell numbers per cornea for CD31+ cells,
Neutrophils (CD11b+, Ly6G+ cells) and CD4+ T cells showed significant reduction in
frequencies the respective cell population in the MMPi treated mice.
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PART-IV
ROLE OF IL-17A IN HSV MEDIATED
CORNEAL ANGIOGENESIS
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In this chapter “our” and “we” refers to me and co-authors. My contribution in the
chapter includes (1) Selection of the topic (2) Compiling and interpretation of the
literature (3) Designing experiments (4) Understanding the literature and interpretation of
the results (5) Providing comprehensible structure to the chapter (6) Preparation of graphs
and figures (7) Writing and editing.

Abstract
Corneal herpes simplex virus (HSV) infection leads to the development of
angiogenesis by causing an imbalance between vascular endothelial growth factor
(VEGF) and its soluble receptor-1 (sVEGFR-1), however the underlying mechanisms are
poorly understood. Here we demonstrate that IL-17A, a cytokine induced after HSV
infection shifts the balance between VEGF-A and sVEGFR-1 and thereby promotes
corneal angiogenesis. Accordingly, HSV infection of mice lacking IL-17 receptor (IL17RAKO) and IL-17A neutralization in WT HSV infected mice resulted in significantly
diminished corneal neovascularization, an outcome of multiple mechanisms. Firstly, IL17A through direct and indirect actions promoted corneal VEGF-A levels by corneal
stromal keratocytes. Secondly, IL-17A enhanced corneal matrix metalloproteinase
(MMP) -2, -7 and -9 expression that additionally improved VEGF-A bioavailability
through increased sVEGFR-1 degradation. Additionally, IL-17A potentiated the
angiogenic response by increased expression of CXCL1/KC and subsequent migration of
neutrophils in the cornea. Moreover, neutrophils contribute to the imbalance between
VEGF-A and sVEGFR-1 by acting as a source of VEGF-A as well as MMPs that degrade
sVEGFR-1. Collectively, the multiple actions of IL-17A acted to increase VEGF-A and
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diminish the anti-angiogenic action of the sVEGFR-1. This could mean that targeting IL17A mediated effects represent a useful therapeutic approach to manage ocular
angiogenesis.

Introduction
Optimal vision demands corneal transparency so that light transmission proceeds
to the retina without interruption. Several mechanisms are employed to achieve
transparency. These include events that suppress angiogenesis and tissue damaging
inflammatory and immune reactions in the pre-retinal tissues (1-3). The control system
lacks perfection and breaks down in response to some injurious events. Infection of the
cornea with herpes simplex virus-1 (HSV) is one such event and this can result in corneal
blindness (stromal keratitis- SK) after frequent recrudescences from latent infection in the
trigeminal ganglion (3, 4). The SK lesions, which largely represent T cell orchestrated
inflammatory reactions set off by the virus (5-7), are one of the commonest infectious
causes of vision loss in developed countries (3). One prominent feature of SK lesions is
the establishment of new blood vessels in the normally avascular cornea (3, 8, 9). Most of
our understanding of the pathogenesis of SK, particularly the role of neovascularization,
comes from studies of animal models where SK is a regular outcome of primary HSV
infection of the cornea (5-7). Although several molecules may participate in corneal
neovascularization, the principal mediator is VEGF-A signaling through the VEGFR-2
receptor (8, 10). Curiously, VEGF-A is synthesized by the normal cornea, but its
angiogenic activity is constrained by its binding to an excess of the soluble form of the
VEGF receptor 1 (sVEGFR-1) that is produced by corneal epithelial cells (2). This
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situation is often referred as the VEGF trap (2, 11-13). The consequence of HSV ocular
infection is a change in the concentration balance between VEGF-A and the soluble
receptor (14), but how this is achieved is not fully understood.
Previous studies have established that HSV infection, either directly or
indirectly, causes the increased production of VEGF-A, but reduces the synthesis
sVEGFR-1 (8, 14-17). Additionally, the inflammatory reaction induced by HSV includes
the infiltration of cells that produce enzymes such as MMP-2, -7 and -9 that degrades
sVEGFR-1, into inactive fragments (14, 18). Since regulation of VEGF levels and
molecules that influence its signaling represent valuable approach to control pathological
angiogenesis (3, 8-10, 14, 19), it is important to understand how the multiple molecules
generated in the inflamed cornea after HSV infection impact on VEGF function. In the
present report, we focus on the cytokine IL-17A which, as we showed recently
(unpublished data), is rapidly upregulated in the eye after HSV infection. Moreover, past
studies had demonstrated that fibroblasts and monocytes exposed in vitro to IL-17 may
produce VEGF-A (20-25). Additionally, IL-17 was shown to play a role in mediating
tumor angiogenesis by causing the proliferation and migration of vascular endothelial
cells into tissue (26). Little is currently known about the participation of IL-17 in ocular
angiogenesis, particularly how it might impact on the efficiency of the VEGF-A trap.
In the present report, we demonstrate that HSV induced IL-17A expression in the
cornea is a critical factor responsible for changing the balance between VEGF-A and
sVEGFR-1. HSV infection of mice lacking IL-17A signaling or neutralization of IL-17A
in WT HSV infected mice showed reduced corneal angiogenic responses. The
mechanisms for diminished angiogenesis were multiple and included reduced corneal
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expression of VEGF-A but no effects on sVEGFR-1 levels by HSV infected IL-17RA-/mice when compared to WT counterparts. Additionally, IL-17A induced IL-6 production
by corneal stromal fibroblasts, and IL-6 in combination with IL-17A acted in concert to
further up-regulate VEGF-A production. Furthermore, IL-17A directly enhanced MMP-9
production by corneal fibroblast cells as well as indirectly affected the corneal MMP-2
and MMP-9 expression after HSV infection. Theses MMPs further increased VEGF-A
bioavailability through increased sVEGFR-1 degradation. Moreover, IL-17A also
induced the expression of a neutrophil chemoattractant, CXCL1/KC in the cornea after
HSV infection. The increased levels of CXCL1/KC in the cornea promoted the migration
of neutrophils at the site of inflammation, which further affected the balance between
VEGF-A and sVEGFR-1 by providing an additional source of pre-formed VEGF-A as
well as sVEGFR-1 degrading MMPs. Taken together our data shows that IL-17A plays a
central role in regulating ocular angiogenesis and does so at least in part by limiting the
efficacy of the VEGF trap.

Material and Methods
Mice, Virus and cell lines. IL-17RA-/- mice on a C57BL/6 background were obtained
from Amgen (Thousand Oaks, CA). C57BL/6 mice were purchased from Harlan Sprague
Dawley, Indianapolis, IN. Animals were housed in the animal facilities approved by the
Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) at
The University of Tennessee and all experimental procedures were in complete
agreement with the Association for research in Vision and Ophthalmology resolution on
the use of animals in research. HSV-1 RE Tumpey viruse was grown in Vero Cell
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monolayers (ATCC no. CCL81, American Type Culture Collection). The virus was
concentrated, titrated, and stored in aliquots at -800 C until use. MK/T-1 cell line
(Immortalised keratocytes from C57/BL6 mouse corneal stroma) was kindly gifted by Dr.
Reza Dana, Schepens Eye Research Institute and Department of Ophthalmology, Harvard
Medical School, Boston MA.
Corneal HSV Infection and Clinical Scoring. Corneal infections of mice were
conducted under deep anaesthesia induced by i.p. injection of avertin as previously
described (8). Mice were scarified on their corneas with 27-gauge needle, and a 3-µl drop
containing 1×104 PFU of virus was applied to the eye. The eyes were examined on
different days pi for the development and progression of clinical lesion by slit-lamp
biomicroscope (Kowa Company, Nagoya, Japan). The progression of SK lesion severity
and angiogenesis of individually scored mice was recorded. The scoring system was as
follows: 0, normal cornea; +1, mild corneal haze; +2, moderate corneal opacity or
scarring; +3, severe corneal opacity but iris visible; +4, opaque cornea and corneal ulcer;
+5, corneal rupture and necrotizing keratitis. The severity of angiogenesis was recorded
as described previously (27). According to this system, a grade of 4 for a given quadrant
of the circle represents a centripetal growth of 1.5 cm towards the corneal center. The
score of the four quadrants of the eye were then summed to derive the neo vessel index
(range 0‐16) for each eye at a given time point.
Sub‐conjunctival Injection. Subconjunctival injections of anti-IL-17 were performed as
described previously (28). Briefly, subconjunctival injections were done using a 2‐cm,
32 gauge needle and syringe (Hamilton, Reno, NV) to penetrate the perivascular region
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of conjunctiva, and the required dose of anti-IL-17 mAb was delivered into
subconjunctival space. Control mice received isotype mAb.
IL-17 Neutralization. C57BL/6 mice were ocularly infected and 0.05 mg of anti-IL-17
was given intraperitoneally (ip) starting from day 7 followed by day 10 and 13 pi. For
local depletion, 5 µg anti-IL-17 mAb was administered by sub-conjunctival injection
either startind from day 1 pi followed by day 3 and day 5 pi for earl y depletion or
starting from day 7 pi followed by day 9, day 11 and day 13 pi for late depletion.
γδ T cell Depletion. C57BL/6 mice were injected 2 days before infection with 500 µg
per mouse of anti-mouse γδ TCR mAb (clone UC3-10A6) followed by 250 µg per mouse
on day of infection.
Flow Cytometry. Corneas were excised, pooled group wise, and digested with 60 U/ml
Liberase for 35 minutes at 370C in a humified atmosphere of 5% CO2. After incubation,
the corneas were disrupted by grinding with a syringe plunger on a cell strainer and a
single-cell suspension was made in complete RPMI 1640 medium. The single cell
suspensions obtained from corneas were stained for different cell surface molecules for
FACS. All steps performed at 40C. Briefly, cell suspension was first blocked with an
unconjugated anti CD32/CD16 mAb for 30 min in FACS buffer. After washing with
FACS buffer, samples were incubated with CD45-allophycocyanin (30-F11), CD11bPerCP (M1/79), Ly6G-PE (1A8) and CD31-PE (MEC13.3) (All from BD BiosciencesPharmingen) for 30 min on ice. Finally, the cells were washed three times and resuspended in 1% para-formaldehyde. The stained samples were acquired with a FACS
Calibur (BD Biosciences) and the data were analyzed using the FlowJo software.
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Quantitative Real-Time PCR (qRT-PCR). Corneal cells were lysed and total mRNA
was extracted using TRIzol LS reagent (Invitrogen). Total cDNA was made with 500 ng
of RNA using oligo(dT) primer. Quantitative PCR was performed using SYBR Green
PCR Master Mix (Applied Biosystem, Foster City, CA) with iQ5 real-‐time PCR detection
ssystme (Bio Rad, Hercules, CA). The expression levels of different molecules were
normalized to β-‐actin using ΔCt calculation. Relative expression between control and
experimental groups were calculated using the 2-‐ΔΔCt formula. The PCR primers used
were as follows
β	
   ACTIN-‐	
   For	
   5’-‐TCCGTAAAGAATCTCATGCC-‐3’,	
   Rev	
   5'-‐ATCTTCATCCTCCTAGGAGC-‐
3'; IFN-‐Υ	
  For	
  5’-‐GGATGCATTCATGAGTATTGC-‐3’,	
  Rev	
  5’-‐GCTTCCTGAGGCTGGATTC-‐
3’; IL17A	
   For	
   5’-‐	
   GCTCCAGAAGGCCCTCAG-‐3’,	
   Rev	
   5’-‐	
   CTTTCCCTCCGCATTGACA-‐3’;
IL6-‐	
  

For	
  

5’-‐	
  

CGTGGAAATGAGAAAAGAGTTGTGC-‐3’,	
  

Rev	
  

5’-‐	
  

ATGCTTAGGCATAACGCACTAGGT-‐3’ TGFβ-‐For	
   5'-‐	
   TTGCTTCAGCTCCACAGAGA-‐3’,	
  
Rev	
  5’-‐	
  TGGTTGTAGAGGGCAAGGAC-‐3’;	
  CCL20	
  -‐	
  For	
  5’-‐GCCTCTCGTACATACAGACGC-‐
3’,	
  Rev5’-‐CCAGTTCTGCTTTGGATCAGC-‐3’.	
  
Western blot analysis. The supernatants from lysed corneal cells were quantified using
BCA protein Assay kit (Thermo scientific, Waltham, MA) using BSA as a standard and
samples with equal protein concentrations were denatured by boiling in Laemmli buffer.
Polypeptides were resolved by SDS-PAGE and transferred onto a PVDF membrane. The
membrane was blocked with 5% BSA in Tris-buffered saline with Tween20 (20 mM Tris
[pH 7.4], 137 mM NaCl, and 0.1% Tween20) overnight at 40C and probed with specific
primary and secondary antibodies. Proteins were detected using chemiluminiscent HRP
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substrate (Millipore, Billerica, MA). The membrane was kept in stripping buffer for 10
min and re-probed using anti-β-actin antibody. The antibodies used were rat anti
sVEGFR-1 (141515; R&D Systems), mouse anti-VEGF-A (EE02; Santa Cruz
Biotechnology, Santa Cruz, CA), mouse anti-β-actin (AC74; Sigma-Aldrich, St Louis
MO), goat anti rat IgG-HRP (R & D Systems), goat anti-mouse IgG-HRP (Santa Cruz
Biotechnology) and donkey anti goat IgG-HRP (Santa Cruz Biotechnology).
Immunofluorescence staining. For immunofluorescence staining, the eyes from naïve
uninfected mice were enucleated, and snap frozen in OCT compound. Six-micron thick
sections were cut, air dried, and fixed in acetone-methanol (1:1) at room -20 0C for 10
min. Sections were blocked with 10% goat serum containing 0.05% Tween20 and 1:200
dilution of Fc block (Clone 2.42G2; BD Biosciences Pharmingen, San Diego, CA). Rat
anti-Ly6G (Clone RB6-8C5; eBioscience) was diluted in 1% BSA containing 0.1%
Triton-X and incubated at room temp for 1 hr. After incubations sections were washed
several times with PBST and then stained with rabbit anti rat Alexa-488 for 45 min. The
corneal sections were repeatedly washed with PBST and mounted with mounting media
containing propidium iodide as a nuclear stain (Vector Laboratories) and visualized under
a Immunofluorescence microscope.
ELISA. The pooled corneal samples were homogenized using a tissue homogenizer and
supernatant was used for analysis. The concentrations of VEGF-A, sVEGFR-1, CXCXL1/KC (R & D Systmes) and IL-6 (eBioscience) were measured by using sandwich ELISA
kits as per the manufacturer’s instructions.
Statistics. Student’s t test was performed to determine statistical significance and data are
expressed as mean ± SEM.
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Results

Lack of IL-17A receptor signaling diminishes severity of HSV induced corneal
angiogenesis
To study the role of IL-17A and IL-17A receptor signaling effects on HSV
induced corneal angiogenesis, IL-17RA-/- mice were ocularly infected with HSV and the
severity of angiogenesis was compared with infected control WT mice. At all time points,
IL-17RA-/- mice showed significantly lesser angiogenesis than WT animals (Fig 4.1AB). The onset of visible angiogenic sprouting was delayed, angiogenesis scores were
lower and more mice had diminished angiogenesis scores in IL-17RA-/- mice as
compared to their WT counterparts (Fig 4.1A). Additionally, not only the frequency but
also the severity of angiogenesis (scores of ≥8) was reduced in mice in the IL-17RA-/group (2 of 8 eyes at day 21) compared to WT counterparts (9 of 11 eyes at day 21) (Fig
4.1B). Analysis by FACS of pooled corneas from IL-17RA-/- and WT mice in each
group at day15 pi revealed reduced frequencies as well as total numbers of CD31+ cells
(a marker for blood vessel endothelium) in IL-17RA-/- as compared to WT animals (Fig
4.1C-E).
Further evidence that IL-17A signaling was involved in HSV induced corneal
angiogenesis came from measuring the outcome of neutralizing anti-IL-17 mAb
treatment of HSV infected WT mice over a period of 15 days. IL-17 neutralization was
started from day 7 pi when angiogenic sprouting became evident, followed by additional
treatment on days 10 and 13 pi (Fig 4.2A). Animals that received the mAb showed a
significant reduction in peak angiogenesis scores as compared to control isotype treated
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mice (Fig 4.2B). Moreover, the frequency of severe angiogenesis (scores of ≥8) was
significantly reduced in animals from the mAb recipients (3 of 8 eyes) as compared to
isotype Ab recipients (7 of 8 eyes) (Fig 4.2C).
Interestingly, local sub-conjunctival administration of anti-ILA mAb showed an
even more profound inhibitory effect on the onset as well as severity of HSV induced
corneal angiogenesis (Fig 4.2D-G). Corneal samples collected at the end of the
experiment revealed reduced frequency as well numbers of CD31+ cells in the IL-17A
neutralized group as compared to isotype mAb recipients (Fig 4.2H-J). Taken together
these data indicate that mice lacking signaling for IL-17A were more resistant to HSV
induced corneal angiogenesis indicating that IL-17A plays a critical role in driving the
neovascularization resulting from HSV infection.

A. IL-17A differentially regulates VEGF-A and sVEGFR-1 expression after HSV
infection
To further study the role of IL-17A in HSV induced corneal angiogenesis, the
levels of VEGF-A and sVEGFR-1 produced by HSV infected corneas was measured by
ELISA, RT-PCR and WB in both WT and IL-17RA-/- mice at various time points pi. As
already described, compared to WT, IL-17RA-/- mice showed diminished levels of
VEGF-A (Fig 4.3A-B), but the level of sVEGFR-1was not reduced and remained
approximately the same as in uninfected control animals (Fig 4.3 C, D). Additionally,
when the ratio of total number of sVEGFR-1 molecules per VEGF-A molecule from
naïve mice was compared with infected animals at varios time points pi, the ratio was
significantly decreased in WT animals at all days pi, but not in IL-17RAKO mice (Fig
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4.3E). Furthermore, depletion of γδ T cells, which act as an early source of IL-17A,
resulted into diminished levels of VEGF-A further confirming the role of IL-17A in
VEGF-A production (Fig 4.3F-G). To further confirm the role of IL-17A in VEGF-A upregulation, IL-17A neutralization was carried out either starting from day 1 until day 7 pi
(Fig 4.3H), or starting from day 7 pi until day 15 pi (Fig 4.3I). Both the depletion
strategies resulted into reduced VEGF-A mRNA expression (Fig 4.3J) as well as reduced
VEGF-A protein production (Fig 4.3K).
Additional in-vitro experiments were performed with an immortalized murine
corneal stromal fibroblast cell line (MK/T-1 cells) to measure the effect of IL-17A
stimulation on the production of both VEGF-A and sVEGFR-1. Stimulation with IL-17A
caused a dose dependent increase of VEGF-A secretion, but had minimal and
insignificant effects on sVEGFR-1 levels as measured by ELISA (Fig 4.3L-N). Taken
together, these in vitro studies also support the idea that the presence of IL-17A could
shift the balance between VEGF-A to its inhibitory sVEGFR-1, making the VEGF-A trap
less efficacious.

B. IL-17A induces IL-6 expression and in combination expands production of
VEGF-A by corneal stromal fibroblasts.
One potential mechanism by which IL-17A acts could be to influence the
expression of other cytokines known to be indirectly involved in angiogenesis such as IL6 and IL-1β (3, 16, 20, 23, 24). To evaluate the possibility, levels of corneal IL-6 were
compared between HSV infected IL-17RA-/- and WT counterparts at various days pi by
RT-PCR. Corneal samples from IL-17RA-/- mice showed diminished expression of IL-6
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at all tested days pi (Fig 4.4A). Moreover, local neutralization of IL-17A during early as
well as late phase of HSV infection (Fig 4.4B) resulted into reduced mRNA expression of
IL-6 on day 7 and day 15 pi (Fig 4.4C). Further in-vitro studies were done to study the
effect of IL-17A on the expression of IL-6/IL-1β and their combined role in the induction
of VEGF-A by corneal stromal fibroblasts (MK/T-1) cells. IL-17A increased the
production by MK/T-1 cells of IL-6 in a dose dependent manner, and addition of anti-IL17A mAb completely blocked IL-17A induced production of IL-6 (Fig 4.4D-E).
Interestingly, IL-17A in combination with IL-6 and IL-1β potentiated VEGF-A
production by corneal stromal fibroblast cells (Fig 4.4 F-H). Taken together, these data
indicated that IL-17A indirectly promoted the expression of VEGF-A through increased
expression of pro-angiogenic cytokines such as IL-6. These cytokines independently as
well as in combination with IL-17A increased the expression of VEGF-A, further
deviating the balance between VEGF-A and sVEGFR-1.

C. IL-17A drives increased expression of various MMPs responsible for sVEGFR-1
degradation
Another mechanism by which IL-17A signaling could influences angiogenesis
was via its effect on the expression of different MMP enzymes that degrade sVEGFR-1,
but not VEGF-A (14, 29, 30), into non-functional fragments. Comparing the corneal
samples from HSV infected IL-17RAKO and WT mice taken at various days pi, levels of
MMP-2, MMP-7 and MMP-9 were reduced in IL-17RAKO mice as compared to WT
(Fig 4.5A-C). Furthermore, neutralization of IL-17A in WT HSV infected mice resulted
into diminished expression of MMP-2, MMP-7 and MMP-9 when compared to isotype
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treated animals (Fig 4.5 D-G). Additionally, in vitro experiments with IL-17A stimulated
MK/T-1 cells also revealed dose dependent increase in MMP-9 mRNA expression as
measured by RT-PCR (Fig 4.5H). This effect was inhibited by the addition of anti-IL17A mAb indicating that it was IL-17A specific. Collectively, these results indicate that
IL-17A could influence the efficacy of the VEGF-A trap by increasing the synthesis of
some MMPs that can cause sVEGFR-1 degradation, making more VEGF-A available to
induce angiogenesis.

C. Additional mechanisms caused by IL-17A affecting efficiency of the VEGF-A
trap
Additional consequences of IL-17A induction following HSV infection might
also contribute indirectly to angiogenesis by increased the synthesis of CXCL1/KC, a
chemoattractant for neutrophils (22, 23, 25, 31-33). The consequent higher infiltration of
neutrophils (CD45+CD11b+ Ly6+ cells), act as a source of VEGF-A as well as sVEGFR-1
degrading MMPs (14, 18, 34). To test this possibility, we measured the levels of
CXCL1/KC between WT and IL-17RAKO mice at various time points. At all times
tested, significantly reduced CXCL1/KC levels were observed in corneas of IL-17RAKO
mice as compared to WT control mice (Fig 4. 6A-B). The role of IL-17A in CXCL1/KC
production was further confirmed by the in-vitro stimulation of MK/T-1 cells with
different concentrations of IL-17A for 24 hr. Unstimulated MK/T-1 cells produced basal
amounts of CXCL1/KC, but the addition of IL-17A even at very low concentrations to
the culture media, increased CXCL1/KC production by 4.5 fold (Fig 4.6 C-D).
Neutralization of IL-17A completely inhibited the CXCL1/KC production by stromal
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fibroblasts indicating a direct role of IL-17A in the upregulation of CXCL1/KC.
Moreover, IL-17A was a more potent inducer of CXCL1/KC, when compared to IL-6
(Fig 4.6 E).
Further evidence for the role of IL-17A in corneal migration of neutrophils post
HSV infection came from comparing the corneal infiltrating neutrophils between HSV
infected WT and IL-17RAKO mice. Accordingly, IL-17RAKO mice had significantly
reduced frequencies and total cell numbers of neutrophils when compared to WT
counterparts (Fig 4.6 F-G). Moreover, in-vivo neutralization of IL-17A in WT HSV
infected mice showed diminished infiltration of neutrophils, further confirming the
critical role of IL-17A in the migration of these cells to the site of inflammation (Fig 4.6
H-M). Collectively, these results indicated that the reduced degradation of sVEGFR-1
and diminished levels of VEGF-A in IL-17RAKO mice as well as post IL-17A
neutralization in WT mice could be the result of diminished expression of CXCL1/KC
and consequent reduced infiltration of neutrophils, which indirectly contribute to the
source of VEGF-A and sVEGFR-1 degrading MMPs.

Discussion
The normal eye employs numerous strategies to maintain the corneal transparency
that is essential for optimal vision. One such inhibitory interaction is between VEGF-A
and sVEGFR-1. With this VEGF-A trap preventing corneal vascularity reaction.
However, conditions such as HSV infection of the cornea disrupts the VEGF-A trap
resulting in corneal neovascularization an essential step in the pathogenesis of SK and
subsequent vision loss (3, 8, 9). In this report, we investigated how IL-17A induced
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following HSV infection of the cornea influences the efficacy of the VEGF-A trap. We
show that IL-17A contributes to changing the balance between VEGF-A and sVEGFR-1
through multiple mechanisms. Accordingly, animals lacking response to IL-17A
signaling because of IL-17 receptor knock out or treatment with neutralizing mAb to IL17A resulted into significant diminished angiogenesis as compared to WT counterparts.
The reduced angiogenesis was the consequence of reduced VEGF-A production, but
retention in levels of sVEGFR-1. Lesser amounts of sVEGFR-1 degrading MMP
enzymes were produced in the absence of IL-17A signaling as were the production of
chemokine and cytokines that contributes indirectly to angiogenesis. In vitro results too
demonstrated that IL-17A stimulated ocular fibroblast produced VEGF-A, but not
sVEGFR-1 along with neutrophil chemokine, CXCL1/KC, sVEGFR-1 degrading
enzyme, MMP-9 and proinflammatory cytokine IL-6 and IL-1β, which are indirectly
involved in angiogenesis. Collectively, our results demonstrated that IL-17A could
influence the HSV induced corneal angiogenesis by targeting multiple pathways leading
to the reduce efficacy of the VEGF-A trap. It is conceivable that targeting IL-17A
mediated effects could prove a better therapeutic option to control of HSV induced
corneal angiogenesis and lesions of SK. Our overall results are summarized in Fig 4.7,
showing how HSV induced IL-17A expression orchestrates various critical events
involved in corneal angiogenesis.
Since neovascularization is a critical step in the pathogenesis of SK,
understanding how it is induced in response to HSV infection could reveal new
approaches for its control. The clue that IL-17A could represent a key event in
neovascularization came from studies in tumor angiogenesis where IL-17A was shown to
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act as an inducer of VEGF-A from fibroblast cells (20, 22, 25, 26). Recently, we
demonstrated that IL-17A is induced early after ocular infection with HSV arising
initially from γδ T cells that are early invaders of the corneal stroma and spontaneous
producers of IL-17A (Unpublished data). However, conceivably the earliest source of IL17A after HSV infection could be the epithelium itself responding to products released by
virus infected cells. Virus infected cells may also be the initial source of VEGF-A the
principal mediator of angiogenesis. However, subsequently the production of VEGF-A
would seem to depend on stimulation of producer cells by IL-17A. Two lines of evidence
supported this notion. Firstly we could show a marked reduction in angiogenesis in
animals unable to respond IL-17A because they lack the IL-17A receptor. Furthermore,
angiogenesis levels were diminished if infected animals were suppressed with anti-IL17A neutralizing mAb. The effect was most evident when the mAb treatment was given
locally starting on day 7 pi a time when angiogenesis had already begun indicating that
IL-17A may exerts its predominant influence after the initial phase of neovascularization.
The overall effect of IL-17A in ocular angiogenesis appeared to be the consequence of
multiple events. These included the stimulation of VEGF-A production from cells in the
stroma, as we could model in vitro, as well as the production by stimulated cells of a
cytokine that attracts neutrophils to the corneal stroma. A second ongoing issue was that
IL-17 had no stimulatory effect on sVEGFR-1 production, a molecule that can bind to
VEGF-A and limits its angiogenic activity. More of relevance, IL-17A induced the
production of MMP-9 from stromal fibroblasts and caused the production of a cytokine s
that recruits neutrophils into the stroma. Neutrophils also act as a source of VEGF-A as
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well as several MMP enzymes that could degrade sVEGFR-1. The overall outcome was a
marked reduction in the efficacy of the VEGF-A trap and enhanced angiogenesis.
Newly developed blood vessels during pathological angiogenesis are often
abnormal, lack normal architecture and are leaky thus permitting the escape of proinflammatory cells/molecules into the corneal stroma (3, 19). Prior studies have shown
the critical role of VEGF-A/VEGFR-2 in mediating HSV induced corneal angiogenesis
(8-10, 14, 16, 17). However, molecular mechanisms responsible for the VEGF-A
induction post HSV infection are still unclear. One important aspect of HSV induced
corneal angiogenesis is the loss of the VEGF-A trap efficacy mainly through increased
synthesis of VEGF-A and reduced expression of sVEGFR-1 along with its degradation
by various MMPs (14). Past studies have shown that early after HSV infection, infected
corneal epithelial or nearby uninfected cells predominantly contribute to the early source
of VEGF-A (16, 17). Additionally, once virus is cleared from the cornea around day 7 pi
(3), innate cells such as neutrophils act as an additional source of VEGF-A during the
clinical stage of SK pathogenesis (3, 14, 18, 34). Although, HSV infection of corneal
epithelial cells have been shown to induce the expression of VEGF-A, various other
factors such as IL-6, CpG oligonucleotide could also induce the VEGF-A expression by
corneal epithelial or stromal fibroblast cells (15, 16). Numerous studies in arthritis and
tumor systems have indicated the pro-angiogenic role of IL-17A, mainly through
induction of VEGF-A, MMP-9, IL-1B and IL-6 (20-23, 25, 26). Since we observed
increased expression of IL-17A early after HSV infection (unpublished data, Part II), it is
conceivable that IL-17A could be modulating the expression of VEGF-A in the cornea
post HSV infection. In consequence, the reduced levels of VEGF-A in IL-17RA-/- mice
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and post IL-17 neutralization in WT mice indicated that IL-17A plays a similar role in the
induction of VEGF-A post corneal HSV infection. Consistent with the findings, in-vitro
data indicated that corneal stromal fibroblasts could also provide a supplementary source
of VEGF-A through IL-17A mediated signaling. Since epithelial cells also express IL17RA, increased VEGF-A expression post HSV infection could be the combined result of
IL-17A mediated paracrine expression of VEGF-A by corneal epithelial as well as
stromal fibroblast cells. However, currently we lack evidence for the IL-17A mediated
effects on corneal epithelial cell expression of VEGF-A. Further studies using corneal
epithelial cell line would shed more light on role of IL-17A and the relative contribution
of epithelial cells to the source of VEGF-A.
In addition to increased VEGF-A expression, reduced levels of sVEGFR-1,
mainly through reduced synthesis along with MMP mediated increased degradation,
potentiate the VEGF-A mediated effects and subsequent corneal angiogenesis post HSV
infection (14, 29). Furthermore, increased degradation of sVEGFR-1 post HSV infection
could also contribute to the source of VEGF-A by releasing pre-formed VEGF-A bound
to sVEGFR-1 (2, 14). HSV infection drives the increased expression of various MMPs,
which selectively degrade sVEGFR-1 into biologically non-active form (14, 18),
contributing to the inefficacy of the VEGF-A trap. Although earlier studies showed that
HSV infection upregulated the expression of MMPs (14, 18), underlying mechanisms for
MMPs upregulation are poorly understood. Our study showed that IL-17A orchestrated
various events following HSV infection. In addition to increased expression of VEGF-A,
IL-17A also upregulated the expression of MMP-9 by corneal stromal fibroblast cells,
which through degradation of sVEGFR-1 enhanced the biological activity of VEGF-A.
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Support for this finding came by observing the levels of various MMPs in the corneas of
HSV infected IL-17RA-/- mice, which showed significantly diminished expression of
MMP-7 and -9. Additionally, reduced degradation of sVEGFR-1 from corneal samples of
IL-17RA-/- mice suggested that IL-17 directly affects the efficacy of the VEGF-A trap
through the expression of various sVEGFR-1 degrading MMPs. Our findings are in
accord with the previously published reports where lack of MMP activity post HSV
infection as observed in MMP-9-/- mice or treatment of HSV infected WT mice with
broad spectrum MMP inhibitor showed diminished angiogenesis (14, 18). Thus our data
indicates that increased expression of IL-17A post HSV infection perturbs the balance
between VEGF-A by directly increasing the expression of VEGF-A as well as MMPs,
which participate in the degradation of sVEGFR-1.
Another important aspect of IL-17A mediated signaling is the upregulation of
CXCL1/KC, a chemoattractant for neutrophils and subsequent neutrophil mediated
effects in the promotion of corneal angiogenesis (22, 23, 25, 31-33). Neutrophils are the
predominant cells that infiltrate the cornea during all stages of SK pathogenesis (14).
Although, neutrophils initially play a protective role in virus clearance (35), subsequently
they contribute to the corneal tissue damage and angiogenesis by providing an additional
source of VEGF-A, various oxy-radicals as well as MMPs (3, 14, 18). IL-17A through
its myriad effects on epithelial and stromal fibroblast cells were also shown to increase
the expression of neutrophil chemoattractant CXCL1/KC and subsequent infiltration of
neutrophils at the site of inflammation (22, 23, 25, 31-33). Since, earlier reports from our
lab showed that HSV infection induces IL-17A expression (unpublished data) as well as
migration of the neutrophils in the cornea (3, 14, 36), it is conceivable that IL-17A may
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contribute to the neutrophil influx by increasing the expression of CXCL1/KC by stromal
fibroblasts. Although, this initial innate immune response early after HSV infection is
essential for viral clearance, subsequent continued migration of neutrophils could set up a
stage for the development of complex SK pathogenesis. Indeed our data showing the
reduced levels of CXCL1/KC, subsequent diminished infiltration of neutrophils along
with reduced angiogenesis in mice lacking IL-17RA signaling and after IL-17
neutralization in WT mice confirmed the previous findings as well as supported the
notion that neutrophil infiltration during clinical stages of SK could promote corneal
angiogenesis. Furthermore, our data also indicated the critical link between HSV
infection and migration of neutrophils through IL-17A mediated increased expression of
CXCL1/KC by corneal stromal fibroblast cells. The diminished levels of CXCL1/KC in
HSV infected IL-17RA-/- mice as well as post IL-17 neutralization indicated the
important role of IL-17A signaling in promoting neutrophil infiltration at the site of
inflammation. Additionally, stimulation of corneal stromal fibroblast with IL-17A
showed significant upregulation of CXCL1/KC even at very low concentration
confirming the role of IL-17A in the induction of CXCL1/KC. Moreover, IL-17A was
found to be a more potent inducer of CXCL1/KC as compared to other known factors
such as IL-6 (16, 37). An important aspect of this finding is the effect of IL-17A on the
efficacy of the VEGF-A trap. It is important to note that IL-17A through increased
expression of CXCL1/KC contributes indirectly to the source of VEGF-A and sVEGFR1 degrading enzymes by promoting the migration of neutrophils (3, 14, 18). In addition,
IL-17A also promoted the expression of other pro-inflammatory cytokines such as IL-1B
and IL-6, which were shown to exert angiogenic effects in HSV induced corneal
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angiogenesis (16, 38-40). Previous studies have shown the important role of IL-17A
signaling in the stabilization and increased mRNA expression of various proinflammatory cytokines and chemokines (22, 23, 33). Accordingly, we found
significantly diminished expression of IL-1B, IL-6 and TNF-A in mice lacking IL-17A
signaling, so confirming earlier findings. Furthermore, IL-6 has been shown to play an
important role in HSV induced corneal angiogenesis, as it promotes the paracrine
expression of VEGF-A by corneal epithelial cells (16). In accord with previously
published reports, our in vitro data showed that IL-17A stimulation of MK/T-1 cells
upregulated the expression of IL-6 and IL-1B. Interestingly, we observed the increased
expression of VEGF-A by MK/T-1 cells when cells were stimulated with IL-17A in the
presence of IL-6 and IL-1B. These results demonstrated that IL-17A could serve as a
critical mediator of various key events responsible for HSV induced corneal
neovascularization.
In summary, this study identifies new functions of IL-17A responsible for HSV
induced corneal angiogenesis. It is conceivable that IL-17A through multiple mechanisms
shifts the balance between VEGF-A and sVEGFR-1 affecting the efficacy of VEGF-A
trap. Mechanisms for this imbalance were numerous which included direct increased
expression of VEGF-A, sVEGFR-1 degrading MMPs, IL-6, IL-1B and neutrophil
chemoattractant. The net effect of IL-17A mediated signals was to increase the levels of
VEGF-A and reduce the synthesis of sVEGFR-1 along with increased MMP mediated
degradation of pre-formed sVEGFR-1 molecules. This degradation of sVEGFR-1 might
also contribute to the source of VEGF-A by being released from its bond to sVEGFR-1 in
the VEGF-A trap. In addition to direct increased expression of VEGF-A, IL-17 mediated
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increased expression of IL-6 and IL-1B potentiated the expression of VEGF-A by corneal
fibroblasts through combined action of all three cytokines. Moreover, IL-17A also
indirectly contributed to the source of VEGF-A through the increased expression of
CXCL1/KC followed by increased migration of neutrophils, which further bring the preformed VEGF-A as well as various sVEGFR-1 degrading MMPs at the site of
inflammation. Since IL-17A signaling controls almost all events in affecting the efficacy
of the VEGF-A trap, it would seem logical to develop therapies targeting IL-17A
mediated effects to control corneal angiogenesis and SK immunopathology, an important
cause of human blindness.
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FIGURE 4.1. IL-17RA KO DISPLAY DIMINISHED HSV INDUCED CORNEAL
ANGIOGENESIS.
To compare the development and progression of corneal angiogenesis, WT and
IL-17RA KO mice were infected with 1×104 PFU of HSV by corneal scarification. (A)
The development of new blood vessels in normally avascular cornea was assessed on day
8, 11, 15 and 21 PI. (B) Corneal Angiogenesis score of individual mice on day 21 PI.
Data represents means ± SEM (n= 8 to 12 mice per group from two independent
experiments; *P<0.03, ***P=0.0003). (C-E) Mice were sacrificed on day 15 PI and
corneas were pooled group wise for flow cytometry analysis. (C) Representative FACS
plots for corneal CD31+ endothelial cells between WT and IL-17RA KO mice. (D-E) Bar
graphs show reduced CD31+ endothelial cell frequencies (D) as well as reduced total cell
numbers per cornea (E) from IL-17RA KO mice group as compared to WT. Data
represents mean ± SEM from two independent experiments (n= 5 for WT and 6 for IL17RA KO mice. Each sample is representative of two corneas).
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FIGURE 4.2. SYSTEMIC AND LOCAL IL-17A NEUTRALIZATION REDUCES SEVERITY OF
HSV INDUCED CORNEAL NEOVASCULARIAZTION.
WT mice were infected with 1×104 PFU of HSV by corneal scarification. (A) For
systemic IL-17A neutralization, animals were injected intraperitoneally with 50 µg antiIL-17A or control IgG1 mAb as indicated. (B) The development of new blood vessels in
normally avascular cornea was assessed on day 8, 11 and 15 PI. (C) Corneal
Angiogenesis score of individual mice on day 15 PI. Data represents means ± SEM (n= 8
corneas per group from two independent experiments; **P=0.0015). (D) For local IL17A neutralization, mice were injected sub-conjunctivally with 5 µg of anti-IL-17A or
control IgG1 mAb as indicated. (E) The development of response in normally avascular
cornea was assessed on day 8, 11 and 15 PI. (F) Corneal angiogenesis score of individual
mice on day 15 PI. Data represents means ± SEM (n= 8 corneas per group from two
independent experiments; **P=0.0003). (G) Representative eye photograph of naïve
uninfected, local isotype mAb or anti-IL-17A mAb treated mice on day 15 PI. In
uninfected mice, cornea is clear and devoid of any blood vessels (left panel). By day 15
PI, new blood vessel development reaches to the center of the cornea in isotype mAb
treated mice (middle panel), but only halfway in anti-IL-17A treated mice (right panel) as
indicated by white arrows. This panel is representative of two independent experiments
with 8 eyes per group. (H-J) Mice from local IL-17A neutralization groups were
sacrificed on day 15 PI and corneas were pooled group wise for flow cytometry analysis.
(H) Representative FACS plots for corneal CD31+ endothelial cells between isotype mAb
and anti-IL-17A mAb treated mice. (I-J) Bar graphs show reduced CD31+ endothelial cell
frequencies (I) as well as reduced total cell numbers per cornea (J) from anti-IL-17A
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treated group as compared to isotype treated group. Data represents mean ± SEM from
two independent experiments (n= 4 and each sample is representative of two corneas).
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FIGURE 4.3. IL-17A DIFFERENTIALLY REGULATES THE CORNEAL VEGF-A AND
SVEGFR-1 EXPRESSION.

WT and IL-17RA KO mice were infected with 1X104 PFU of HSV in PBS or
mock infected with only PBS by corneal scarification. (A) VEGF-A mRNA expression
was examined and compared between WT and IL-17RAKO mice by quantitative realtime PCR (qRT-PCR). VEGF-A mRNA levels in mock-infected mice were set to 1 and
used for relative fold up-regulation at various days PI. Data represents means + SEM
from two independent experiments (n=2 and each sample is representative of 8 corneas).
(B) Corneal VEGF-A protein levels were analyzed from WT and IL-17RAKO mice at
indicated time points. Data show mean values + SEM from three different independent
experiments (n=3 and each sample is representative of 8 corneas). (C) sVEGFR-1 mRNA
expression was examined and compared between WT and IL-17RAKO mice by
quantitative real-time PCR (qRT-PCR). sVEGFR-1 mRNA levels in mock-infected mice
were set to 1 and used for relative fold change at various days PI. Data represents means
+ SEM from two independent experiments (n=2 and each sample is representative of 8
corneas). (D) Corneal sVEGFR-1 protein levels were analyzed from WT and IL17RAKO mice at day 7 PI. Data show mean values + SEM from three different
independent experiments (n=3 and each sample is representative of 8 corneas). (E) Ratio
of total number of sVEGFR-1 molecules per VEGF-A molecule from naïve (D0) and
infected corneas at different days PI were compared between WT and IL-17RAKO mice.
Ratios were calculated. The total number of molecules for sVEGFR-1 and VEGF-A were
calculated using protein quantities obtained by ELISA and multiplying it with molecular
weight respective protein and Avogadro’s number. Data show mean values + SEM from
	
  

176	
  

three different independent experiments (n=3 and each sample is representative of 8
corneas). (F) gamma delta T cell depletion was carried out using anti-gamma delta TCR
antibody (500 ug per mice) as indicated. (G) Corneal VEGF-A protein levels were
analyzed and compared between isotype and anti-gamma delta TCR mAb treated mice at
day 2 PI. Data show mean values + SEM from two different independent experiments
(n=2 and each sample is representative of 8 corneas). Local neutralization of IL-17A was
carried out using anti-IL-17A mAb by sub-conjunctival injection during early (H) and
late (I) stages of HSV infection as indicated. (J) VEGF-A mRNA expression was
examined and compared between isotype and anti-IL-17A mAb treated mice by
quantitative real-time PCR (qRT-PCR). VEGF-A mRNA levels in mock-infected mice
were set to 1 and used for relative fold up-regulation at day 7 PI. Data represents means +
SEM from two independent experiments (n=2 and each sample is representative of 8
corneas). (K) Corneal VEGF-A protein levels were analyzed and compared between
isotype and anti-IL-17A mAb treated mice at day 7 PI. Data show mean values + SEM
from two different independent experiments (n=2. Each sample consisted of 8-pooled
corneas). (M-O) MK/T-1 cells (Corneal stromal keratocytes) were stimulated under
different concentrations of IL-17 in the presence or absence of anti-IL-17A mAb for 24
hrs. Supernatants were collected for VEGF-A protein estimation by ELISA and cells
were collected and pooled for analysis of VEGF-A and sVEGFR-1 mRNA expression by
qRT-PCR. The mRNA levels in control media were set to 1 and used for relative fold upregulation at various days PI. (L) IL-17A stimulated VEGF-A production by MK/T-1
cells in a dose dependent manner. Data represents means + SEM from two independent
experiments (n=6). Relative fold change in VEGF-A (M) and sVEGFR-1 (N) mRNA
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expression as compared to control media. Data represents means + SEM from two
independent experiments (n=2 and each sample is representative of pooled cells from 3
different wells).
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FIGURE 4.4. IL-17A STIMULATES IL-6 PRODUCTION BY CORNEAL STROMAL
FIBROBLAST CELLS AND BOTH THE CYTOKINES FURTHER STIMULATE VEGF-A
PRODUCTION.

WT and IL-17RA KO mice were infected with 1X104 PFU of HSV in PBS or
mock infected with only PBS by corneal scarification. (A) IL-6 mRNA expression was
examined and compared between WT and IL-17RAKO mice by qRT-PCR. (B) Local
neutralization of IL-17A was carried out using anti-IL-17A mAb by sub-conjunctival
injection during early () and late () stages of HSV infection as indicated. (C) IL-6 mRNA
expression was examined and compared between isotype and anti-IL-17A mAb treated
mice by quantitative real-time PCR (qRT-PCR). IL-6 mRNA levels in mock-infected
mice were set to 1 and used for relative fold up-regulation at various days PI. Data
represents means + SEM from two independent experiments (n=2 and each sample is
representative of 8 corneas). MK/T-1 cells (Corneal stromal keratocytes) were stimulated
under different concentrations of IL-17 in the presence or absence of anti-IL-17A mAb
for 24 hrs. Supernatants were collected for IL-6 protein estimation by ELISA and cells
were collected and pooled for analysis of IL-6 mRNA expression by qRT-PCR. ()
Relative fold change in IL-6 mRNA expression as compared to control media. Data
represents means + SEM from two independent experiments (n=2 and each sample is
representative of pooled cells from 3 different wells). The mRNA levels in control media
were set to 1 and used to relative fold change in mRNA expression. () IL-17A stimulated
IL-6 production by MK/T-1 cells in a dose dependent manner. Data represents means +
SEM from two independent experiments (n=6). (N) MK/T-1 cells (Corneal stromal
keratocytes) were stimulated under different concentrations of IL-17A and IL-6 for 24
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hrs. Supernatants were collected for VEGF-A protein estimation by ELISA. VEGF-A
production by MK/T-1 cells under different concentrations of IL-17A and IL-6 as
indicated.
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FIGURE 4.5. IL-17A PROMOTES MMP-2, -7 AND -9 EXPRESSION AND AFFECTS VEGF-A
BIOAVAILABILITY THROUGH SVEGFR-1 DEGRADATION.

WT and IL-17RA KO mice were infected with 1X104 PFU of HSV in PBS or
mock infected with only PBS by corneal scarification. (A) MMP-2, (B) MMP-7 and (C)
MMP-9 mRNA expression were examined and compared between WT and IL-17RAKO
mice by qRT-PCR. (D) Local neutralization of IL-17A was carried out using anti-IL-17A
mAb by sub-conjunctival injection during early and later stages of HSV infection as
indicated. (E) MMP-2, (F) MMP-7 and (G) MMP-9 mRNA expression were examined
and compared between isotype and anti-IL-17A mAb treated mice by quantitative realtime PCR (qRT-PCR). MMP-2, -7 and -9 mRNA levels in mock-infected mice were set
to 1 and used for relative fold up-regulation at various days PI. Data represents means +
SEM from two independent experiments (n=2 and each sample is representative of 8
corneas). (H) MK/T-1 cells were stimulated under different concentrations of IL-17 in the
presence or absence of anti-IL-17A mAb for 24 hrs. Cells were collected and pooled for
analysis of MMP-9 mRNA expression by qRT-PCR. () Relative fold change in MMP-9
mRNA expression as compared to control media. Data represents means + SEM from
two independent experiments (n=2 and each sample is representative of pooled cells from
3 different wells). The mRNA levels in control media were set to 1 and used to relative
fold change in mRNA expression.
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FIGURE 4.6. IL-17A PROMOTES NEUTROPHIL INFILTRATION IN THE CORNEA AFTER
HSV INFECTION THROUGH CXCL1/KC INDUCTION.
WT and IL-17RA KO mice were infected with 1X104 PFU of HSV in PBS or
mock infected with only PBS by corneal scarification. (A) CXCL1/KC mRNA
expression was examined and compared between WT and IL-17RAKO mice by
quantitative real-time PCR (qRT-PCR). CXCL1/KC mRNA levels in mock-infected mice
were set to 1 and used for relative fold up-regulation at various days PI. Data represents
means + SEM from two independent experiments (n=2 and each sample is representative
of 8 corneas). (B) Corneal CXCL1/KC protein levels were analyzed from WT and IL17RAKO mice at indicated time points. Data show mean values + SEM from three
different independent experiments (n=3 and each sample is representative of 8 corneas).
MK/T-1 cells (Corneal stromal keratocytes) were stimulated under different
concentrations of IL-17 in the presence or absence of anti-IL-17A mAb for 24 hrs.
Supernatants were collected for VEGF-A protein estimation by ELISA and cells were
collected and pooled for analysis of VEGF-A and sVEGFR-1 mRNA expression by qRTPCR. The mRNA levels in control media were set to 1 and used for relative fold upregulation at various days PI. (C) IL-17A stimulated CXCL1/KC production by MK/T-1
cells in a dose dependent manner as analyzed by qRT-PCR (top) and ELISA (bottom).
(D) IL-17A was more potent inducer of CXCL1/KC as compared to IL-6. Data represents
means + SEM from two independent experiments (n=6). (N) HSV infected WT and IL17RAKO Mice were sacrificed on day 1, 2 and 15 PI and corneas were pooled group
wise for flow cytometry analysis. (E) Representative FACS plots for corneal CD45+
CD11b+ Ly6G+ neutrophils between WT and IL-17RA KO mice. (F) Bar graphs show
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reduced CD45+ CD11b+ Ly6G+ neutrophil numbers per cornea from IL-17RA KO mice
group as compared to WT. (G) Local neutralization of IL-17A was carried out using
anti-IL-17A mAb by sub-conjunctival injection during early (left panel) and late (right
panel) stages of HSV infection as indicated. (H) CXCL1/KC mRNA expression was
examined and compared between isotype and anti-IL-17A mAb treated mice by
quantitative real-time PCR (qRT-PCR). CXCL1/KC mRNA levels in mock-infected mice
were set to 1 and used for relative fold up-regulation at various days PI. Data represents
means + SEM from two independent experiments (n=2 and each sample is representative
of 8 corneas). Mice from local IL-17A neutralization groups were sacrificed on day 15 PI
and corneas were pooled group wise for flow cytometry analysis. (I) Representative
FACS plots for corneal CD45+ CD11b+ Ly6G+ neutrophils between isotype mAb and
anti-IL-17A mAb treated mice. (J) Bar graphs show reduced total CD45+ CD11b+ Ly6G+
neutrophils numbers per cornea from anti-IL-17A treated group as compared to isotype
treated group. (Data is representative of one experiment from 4-pooled corneas). Corneal
sections from HSV infected corneas of isotype and anti-IL-17A mAb treated mice were
analyzed by immunofluorescence microscopy with antibody specific for Ly6G (green).
Sections were counterstained with propidium idodide (red) for nuclear staining. Images
are representative of 6 corneas from two independent experiments. Bars, um.

	
  

186	
  

	
  

187	
  

FIGURE 4.7. SCHEME DEPICTING VARIOUS CRITICAL EVENTS ORCHESTRATED BY IL17A AFTER HSV INFECTION IN CAUSING CORNEAL ANGIOGENESIS.
(A) Model proposing the critical role of IL-17A in the deviation of physiological balance
between VEGF-A and sVEGFR-1 after HSV infection. (B) Mechanisms by which IL17A promotes corneal angiogenesis after HSV infection. Normally, naïve uninfected
cornea constitutively secretes large amounts of sVEGFR-1 and small amounts of VEGFA. This leads to a perfect physiological balance between these two molecules, sVEGFR-1
counteracting angiogenic properties of VEGF-A. The net result is the absence of any
blood vessels in normally uninfected corneas (left panel). However, early after HSV
infection there is increased expression of IL-17A in the cornea, which is mainly
contributed by early innate cells such as γδ T cells. The increased levels of IL-17A then
further contributes to the increased VEGF-A expression by direct stimulation of corneal
stromal fibroblast cells as well as indirectly through increased production of IL-6 which
in turn in combination with IL-17A further promotes VEGF-A production. Moreover,
HSV infection of corneal epithelial cells as well as IL-17A mediated signaling also
downregulates sVEGFR-1 expression in the cornea. In addition to reduced expression of
sVEGFR-1, IL-17A also promotes expression of MMP-9, which further affects the
VEGF-A bioavailability by increased sVEGFR-1 degradation. This in turn leads to more
physiologically active VEGF-A, which is free from inhibitory actions of sVEGFR-1. This
free VEGF-A drives the initial angiogenic sprouting early after HSV infection (middle
panel). During later stages of SK, when replicating virus is cleared off from the cornea,
IL-17A also promotes the CXCL1/KC expression, which promotes the migration of
neutrophils in the inflamed cornea. These neutrophils act as an additional source of pre	
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formed VEGF-A as well as MMPs that contribute to sVEGFR-1 degradation. These
events in addition to direct stimulatory effects of IL-17A on VEGF-A, IL-6 and MMP-9
production, further deviates the balance between VEGF-A and sVEGF-1 and leads to the
development of corneal angiogenesis as observed during late stages of SK (Right Panel).
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